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Abstract 
The cause of cardiac pathology in a significant number of patients with heart failure is 
unclear. Although chronic inflammatory changes may contribute toward progressive heart 
failure, whether low-grade chronic systemic inflammation, produced by infective processes or 
obesity accounts in-part for the development of cardiac dysfunction and heart failure requires 
further study. In this regard, although lipopolysaccharide (LPS) administration, an inflammatory 
mediator derived from the walls of gram negative organisms has been shown to produce an 
increased cardiomyocyte apoptosis, the lowest dose of LPS previously employed is 
commensurate with doses that produce vascular shock. Hence this does not reflect the impact 
of inflammatory changes produced by low-grade systemic infections. Moreover, although 
inflammatory substances have been shown to be released from adipose tissue and obesity is a 
cause of cardiac dysfunction and heart failure, it is uncertain to what extent inflammatory 
changes mediate obesity-induced myocardial dysfunction. To clarify the role of LPS and 
obesity-induced inflammation as potential causes of cardiac damage and dysfunction, in the 
present dissertation I therefore evaluated the influence of pyrogenic, but non-septic doses of 
LPS on cardiomyocyte apoptosis and cardiac systolic function in rats and the contribution of 
inflammation as indexed by circulating high sensitivity C-reactive protein concentrations (hs-
CRP) to the relationship between obesity and myocardial systolic function in humans. 
In normal rats, core body temperature (surgically implanted [in the peritoneal cavity], 
temperature-sensitive radiotransmitters), cardiomyocyte apoptosis (Terminal Deoxynucleotidyl 
Transferase Mediated dUTP Nick End Labeling [TUNEL]) staining) and left ventricular (LV) 
systolic function (two-dimensional directed M-mode echocardiography) were evaluated following 
two doses of LPS (250 µg/kg), derived from Eschericia coli, delivered 24 hours apart. Cardiac 
assessments were performed 6 hours after the second LPS dose to ensure that cardiac 
measurements were obtained at the time of a febrile response, whilst the first LPS dose was 
employed to ensure that a sufficiently long period had occurred for apoptotic cell death to be 
iii 
 
detected using a TUNEL system. In this study LPS was able to induce a febrile response 
(p<0.05, n=26, compared to normal circadian rhythm), yet failed to produce an increased 
cardiomyocyte apoptosis or decreased LV systolic chamber (LV endocardial fractional 
shortening-FSend) or myocardial (LV midwall fractional shortening-FSmid) function. 
In 292 randomly selected participants from an urban, developing community not 
receiving antihypertensive therapy, I also assessed the independent relationship between 
indices of obesity or hs-CRP and LV FSend and FSmid. In this study indices of adiposity 
including waist circumference (partial r=0.35, p<0.0001) were independently related to log hs-
CRP. Furthermore, waist circumference was independently and inversely associated with 
FSmid (standardized β-coefficient= -0.19±0.07, p<0.01), but not with FSend. Although log hs-
CRP was associated with FSmid on bivariate analysis, no independent relationship between 
these variables was noted (p=0.21). Furthermore, with the inclusion of both waist circumference 
and log hs-CRP in the same regression model, waist circumference remained independently 
associated with FSmid (standardized β-coefficient= -0.18±0.08, p<0.05). 
In conclusion, the results of the present dissertation do not support a role for pyrogenic, 
but non-septic doses of LPS in mediating cardiomyocyte apoptosis or dysfunction or a role for 
low grade inflammation, as indexed by hs-CRP concentrations in mediating obesity-induced 
myocardial systolic dysfunction.  
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Preface 
The impetus for the work described in the present dissertation was driven by the need to 
adequately address the potential role of low grade systemic inflammation in contributing toward 
the development as opposed to the progression of heart failure, particularly in a country such as 
South Africa. In this regard, there is no question that heart failure produces low-grade systemic 
inflammation, and that this could contribute toward progressive heart failure. However, there is 
little evidence to suggest that low-grade inflammation may cause the development of heart 
failure. In South Africa, a considerable proportion of patients with chronic heart failure develop 
cardiomyopathies of unknown origins (idiopathic dilated cardiomyopathy). Whether this has a 
genetic, environmental or combined basis as a cause of the disease is uncertain. South Africa is 
also a country where infectious diseases, often chronic infections, play a considerable role in 
morbidity and mortality. Furthermore, there is presently an epidemic of obesity in South Africa 
and obesity is a source of chronic inflammation. It is therefore not unreasonable to hypothesise 
that obesity or chronic low-grade systemic infections could contribute toward the development of 
cardiac dysfunction and ultimately heart failure. However, there are outstanding issues with 
respect to the role of low-grade inflammation produced by infectious diseases and obesity in the 
development of cardiac dysfunction and heart failure. 
In the present dissertation I undertook two studies which were designed to answer basic 
questions. The first question was whether low-grade inflammation produced by components of 
infective agents could promote cardiomyocyte apoptosis, an important pathophysiological 
process that mediates heart failure. In this regard, previous studies had demonstrated that this 
effect could occur, but only used doses of the component of infective agents that is now 
recognized as producing septic (vascular) shock. In the present dissertation I therefore 
evaluated this hypothesis with a pyrogenic, but non-septic dose. Obviously in this study I 
assessed this hypothesis in animal models where cardiac tissue is readily available. I also 
evaluated whether inflammation, as indexed by circulating concentrations of an inflammatory 
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substance could account for the relationship that exists between obesity and cardiac systolic 
dysfunction. In this study I employed a randomly selected community sample with a high 
prevalence of obesity-associated increases in circulating concentrations of inflammatory 
markers. This study was conducted largely because no previous studies had assessed whether 
circulating markers of inflammation could in-part account for the relationship between indices of 
obesity and cardiac function. 
The dissertation begins with a review chapter which highlights the current understanding 
and controversies in the field and leads the reader through a series of arguments in support of 
conducting the studies described in the present dissertation. The first chapter ends with a 
summary of the problem statements and the aims of the dissertation. Chapter 2 outlines the 
methodology employed, chapter 3 describes the results and chapter 4 summarizes the results 
and underscores the novelty of the findings by placing the studies in the context of our present 
understanding of the field, indicating how the work of the dissertation extends our knowledge 
within the field. Moreover, this chapter highlights the implications of the findings and the 
limitations of the studies performed, providing suggestions as to the way forward. The work 
presented in this dissertation will be prepared for publication, once sample sizes are sufficient to 
improve statistical power and once further long-term studies have been completed.      
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Chapter 1 
 
 
Introduction 
 
Inflammation as a potential pathophysiological mechanism 
responsible for chronic myocardial damage or dysfunction. 
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1.0 Introduction 
 
Heart failure is a condition that contributes to a substantial proportion of morbidity and 
mortality. Indeed, from the time of diagnosis, survival rates are comparable to those of 
malignancies with the worst possible outcomes (Cowie et al 2000, Stewart et al 2001, Hobbs et 
al 2004, Lenfant et al 1994). Because of the appalling outcomes in patients with heart failure, 
and the marked burden to health care systems and patients alike produced by heart failure, over 
the past two-to-three decades there has been a considerable number of studies that have been 
performed to attempt to improve the current situation. 
The past two-to-three decades have been highly successful with respect to research into 
an understanding of the pathophysiological mechanisms responsible for the progressive decline 
in cardiac function in heart failure, once heart failure is established. The identification of these 
mechanisms has culminated in a number of novel therapeutic approaches including the use of 
blockers of the renin-angiotensin-aldosterone system and β-blockers (Hunt et al 2001). 
However, in comparison to the success achieved with studies evaluating the mechanisms of the 
progression of heart failure once it is established, research into the mechanisms responsible for 
the development of heart failure has been comparatively less successful. In this regard there 
are still many aspects of heart failure and causes of heart failure where the pathophysiological 
mechanisms still require further elucidation. 
Identifying the pathophysiological mechanisms responsible for the development of heart 
failure is particularly important in developing countries, such as South Africa. Indeed, a recent 
clinical audit conducted in a developing community in South Africa, indicates that the burden of 
cardiovascular disease in a hospital setting appears to be through hospitalizations or referrals 
for heart failure (Sliwa et al 2008, Stewart et al 2008). An important question that emerges from 
these data is whether this apparently high prevalence of heart failure in hospital settings in 
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emerging communities (Sliwa et al 2008, Stewart et al 2008) represents the outcomes of a 
failed health care system in general, or a high prevalence of disease processes the 
pathophysiology of which is uncertain. 
Notwithstanding an important role for rheumatic heart disease (that may nevertheless be 
diminishing) and a potentially increasing role for ischaemic heart disease as causes of heart 
failure in emerging communities (Stewart et al 2008), of the causes of heart failure in these 
communities, the burden of heart failure is nevertheless mainly through hypertension and 
idiopathic dilated cardiomyopathy (dilated cardiomyopathy of unknown origin) with idiopathic 
dilated cardiomyopathy being the predominant cause (Stewart et al 2008). Although there are a 
number of hypotheses regarding the pathophysiology of idiopathic dilated cardiomyopathy, such 
as genetic causes (in familial dilated cardiomyopathy) (Hershberger et al 2005), the end stage 
of a myocarditis (Liu and Mason 2001), an immunological disorder (Luppi et al 1998, 
Brooksbank et al 2005a and b), or through excessive alcohol consumption and a concomitant 
thiamine deficiency (wet beriberi) (Olubodun et al 1996, Seftel 1972), to-date no clear cause for 
this condition has been identified. Thus, there is no question that hypotheses regarding the 
potential pathophysiological mechanisms of heart failure of unknown origin (idiopathic) in 
emerging communities need to be pursued. The consequences of these outcomes may be that 
novel approaches that prevent the development of heart failure will emerge. 
In the present dissertation I tested the hypothesis that low grade inflammatory states 
mediated by chronic infections or obesity may contribute toward cardiac damage or dysfunction. 
These hypotheses were developed, as it is acknowledged that in emerging communities in 
Africa infective diseases play a significant role in contributing toward morbidity and mortality 
(Maher et al 2010, Nsubuga et al 2010), but there is currently little evidence to suggest that this 
morbidity and mortality related to infections is in-part through the development of heart failure. In 
addition, there is simultaneously an epidemic of obesity in South Africa (Puoane et al 2002) and 
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as shall be reviewed in the present chapter, obesity is considered to represent a chronic 
inflammatory state (Berg et al 2005). As shall also be reviewed in the present chapter, although 
obesity is associated with adverse effects on the heart, independent of other risk factors, 
whether these adverse effects are mediated by obesity-induced chronic inflammation is still 
uncertain. 
In the present dissertation I therefore considered the possibility that if low grade 
inflammatory states mediated by either systemic infections (unrelated to the heart), or obesity 
can produce cardiac damage or dysfunction, these changes, if they persist for some time, may 
contribute toward progressive myocardial abnormalities and subsequently to cardiac dilatation 
and hence heart failure. These hypotheses can only be confirmed in longitudinal studies in large 
population samples. However, the studies performed in the present dissertation were conducted 
to test the hypotheses that low grade inflammation, produced by an infection or obesity, may 
indeed mediate myocardial damage or dysfunction. Data to show a relationship between 
obesity-induced inflammatory changes or low grade infection and cardiac damage or 
dysfunction would provide the “proof-of-principle” required to support a large scale clinical study. 
In the present chapter I will therefore first describe the current evidence to suggest that 
infective states, where the origin of the infection is distant to the heart, could produce 
myocardial damage. I will also underscore the limitations of this evidence with respect to 
contributing to a hypothesis that low grade systemic infections may ultimately promote 
myocardial damage and hence heart failure. Second, I will describe the evidence to suggest that 
obesity may contribute toward myocardial damage, highlighting the data that supports or refutes 
a notion that these effects could occur through an impact of inflammatory mediators. Moreover, 
throughout the introduction to the present dissertation I will highlight the principle reasons for 
conducting the studies presented in the present dissertation. 
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Prior to developing the hypotheses that inflammation mediated by low-grade infective 
states or obesity may promote myocardial damage and ultimately contribute toward the 
development of heart failure, I will first highlight the evidence to indicate that inflammation, 
mediated by the presence of heart failure itself, may contribute toward progressive heart failure. 
This dissertation would be incomplete without this discussion, as historically, the hypothesis that 
inflammatory changes contribute to cardiac dysfunction has largely emerged from these studies.  
 
2.0 Inflammation produced in heart failure may contribute toward progressive cardiac 
dysfunction. 
 
The initial evidence that suggested that heart failure could be determined in-part, by a 
chronic inflammatory state, was provided by studies conducted in patients with heart failure who 
were free of infections at the time. In this regard early studies suggested an important role for 
increased circulating cytokine concentrations in heart failure. Indeed, concentrations of the pro-
inflammatory cytokine, tumour necrosis factor-α (TNF-α), were noted to be increased in patients 
with heart failure despite the absence of clinical evidence for an infection (Levine et al 1990, 
Torre-Amione et al 1996b, Matsumori et al 1994). Moreover, increases in circulating cytokine 
concentrations in patients with heart failure were associated with more severe heart failure and 
pump dysfunction (Torre-Amione et al 1996b). Importantly, increased circulating concentrations 
of pro-inflammatory cytokines were observed to be decreased by heart failure therapy, including 
β-adrenergic blockers, and these decreases in circulating cytokine concentrations were also 
noted to be associated with an improved pump function (Mayer et al 2010, Cinquegrana et al 
2005). 
The origin of the increases in circulating pro-inflammatory cytokines in patients with 
heart failure, who have no clinical evidence of an infection, could be from a number of sources. 
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The inflammation may be intra-cardiac or systemic in origins (Torre-Amione et al 1996a, Torre-
Amione et al 1999, Doyama et al 1996). Both sources of inflammation could contribute towards 
the progression of heart failure (Mann, 2002). What are the extra-cardiac sources of 
inflammation? Stimulation of cytokine production in heart failure could emanate from increased 
circulating concentrations of endotoxins (lipopolysaccharides) derived from the gastrointestinal 
tract (because of gastrointestinal oedema causing an increased permeability of the epithelial 
lining to endotoxins) (Niebauer et al 1999, Genth-Zotz et al 2002). Furthermore, a sustained 
TNF-α over-production has been reported to occur ex vivo in white cells obtained from patients 
with idiopathic dilated cardiomyopathy (Aukrust et al 1999, Brooksbank et al 2005a and 2005b). 
In one study, this effect persisted despite haemodynamic improvement subsequent to treatment 
with standard medical care (Brooksbank et al 2005b) and occurred independent of increases in 
circulating endotoxin concentrations, or an increased sensitivity of white cells to endotoxin 
stimulation (Brooksbank et al 2005a). The excessive white cell TNF-α production in patients with 
heart failure in that study (Brooksbank et al 2005a) was attributed to immune-mediated 
mechanisms, but the source of the immune response was not identified. What is the intra-
cardiac source of inflammation? In this regard, as TNF-α is expressed in the myocardium, 
particularly the failing myocardium (Torre-Amione et al 1996a, 1996b, Doyama et al 1996), it is 
also possible that the heart itself is a source of increased circulating cytokines in patients with 
heart failure.  
As previously reviewed (Mann 2002), pre-clinical studies have confirmed the clinical 
findings of increased circulating cytokine concentrations and an enhanced myocardial TNF-α 
expression in cardiac pathology, a change that may be mediated in part by increased 
angiotensin II (Kalra et al 2002). Furthermore, also as previously reviewed (Mann 2002, Kelly 
and Smith 1997), preclinical studies have suggested that pro-inflammatory cytokines, such as 
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TNF-α, could act on the myocardium to promote myocardial damage and dysfunction and the 
mechanisms thereof.  
Figure 1.1 outlines the mechanisms by which TNF-α exerts deleterious effects on the 
myocardium. Briefly, these mechanisms include cardiomyocyte apoptosis, extracellular matrix 
degradation, and reduced contractility. Cardiomyocyte apoptosis occurs as a result of three 
different mechanisms, one of which is the TNF-α activation of macrophages (Tavener et al 
2005), as well as the TNF-α inhibition of cAMP, both of which cause a reduction of cytochrome c 
activity, thereby activating caspases and resulting in apoptosis (Chagnon et al 2005, Prabhu 
2004). A second mechanism is through the production of nitric oxide, which results in impaired 
mitochondrial respiration, resulting in apoptosis (Tavener et al 2005, Prabhu 2004, Suzuki et al 
2007). A third mechanism is via a JNK signaling pathway which causes apoptosis (Dutta et al 
2006). 
Extracellular matrix degradation is the result of TNF-α binding to membrane associated 
neutral sphingomyelinase, which results in ERK1/2 signalling, and subsequent Urokinase 
Plasminogen Activator (uPA), as well as Matrix metalloproteinase-2 (MMP-2) and matrix 
metalloproteinase-9 (MMP-9) activation. These events result in matrix degradation (Cheng et al 
2009). 
Reduced contractility is the result of the activation of membrane associated neutral 
sphingomyelinase which causes an increased ceramide production. Ceramide produces 
sphingosine, which inhibits the release of calcium from the ryanodine receptor and ceramide 
inhibits the internal calcium channel (Prabhu et al 2004).  
Together, all of the clinical and preclinical studies described in the aforementioned 
discussion have provided sufficient evidence to suggest that blockade of the pro-inflammatory 
cytokine, TNF-α, may have useful therapeutic benefits in heart failure. These data thus 
8 
 
prompted the initiation of a number of clinical studies to test this hypothesis. Unfortunately, the 
use of agents that block TNF-α effects in patients with heart failure, were discontinued at an 
early stage, as mortality appeared to increase rather than decrease in the group of patients 
receiving the TNF-α blockers (Chung et al 2003, Mann et al 2004). Although a number of 
reasons have been provided to explain these data, including a suggestion that inflammatory 
effects on the heart may have in fact increased, rather than decreased with these agents (Mann 
2004, Clark et al 1998, Anker and Coats 2002), these studies have nevertheless generated 
some doubt as to the potential role of TNF-α and indeed pro-inflammatory cytokines in heart 
failure. 
          In contrast to the outcome of the clinical studies demonstrating a potential deleterious 
effect of blockade of pro-inflammatory cytokines (Anker and Coats 2002), there is nonetheless 
evidence to suggest that alternative agents, with general inhibitory effects on immune function, 
could produce benefits in heart failure. Indeed, the immunomodulatory agent pentoxifylline has 
been demonstrated to improve cardiac function in patients with heart failure and these effects 
are associated with reductions in circulating concentrations of TNF-α and other pro-
inflammatory cytokines (Sliwa et al 1998, Martich et al 1992). 
Nevertheless, the beneficial effects on cardiac function in patients with heart failure 
mediated by pentoxifylline (Sliwa et at al 1998, Martich et al 1992) may not have been produced 
as a consequence of the immunomodulatory properties of pentoxifylline as originally  
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Figure 1.1. Cellular mechanisms of the deleterious effects of cytokines on the myocardium. Red 
arrows depict an inhibitory pathway; green arrows depict a stimulatory pathway. NF-kB, nuclear 
factor kappa B; JNK, c-Jun N-terminal Kinase, MAPK, membrane-associated protein kinase; 
IRAK-1,Interleukin-receptor associated kinase-1 ; NO, nitric oxide; TNF-α, tumour necrosis 
factor-α; NSM,membrane associated neutral sphingomyelinase; Cer, ceramide; Sph, 
Spingomyelin; EC, extracellular; TIMP, Tissue Inhibitory Matrix Metalloproteinase, MMP, matrix 
metalloproteinase; cAMP, cyclic adenosine monophosphate; uPA,urokinase plasminogen 
activator. The figure summarises pathways supported by the following references: Prabhu et al 
2004; Liu et al 2008; Cheng et al 2009; Suzuki et al 2007;Chagnon et al 2005; Tavener et al 
2005. 
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suggested by the authors. Indeed, pentoxifylline has been shown to produce potent inotropic 
effects through phosphodiesterase inhibitory properties (Osadchii et al 2005). In this regard, 
phosphodiesterase inhibitors, such as amrinone, milrinone and pentoxifylline, are well 
recognized as substances that increase intracellular cyclic adenosine monophosphate 
concentrations and hence mediate positive inotropic and lusitropic effects. Thus, the role of pro-
inflammatory cytokines in the progression of heart failure still remains uncertain. 
 
3.0 Systemic infections may produce myocardial damage and dysfunction 
 
There is no question that infections of the myocardium (myocarditis) can produce 
marked myocardial damage and dysfunction with subsequent cardiac dilatation and pump 
dysfunction (Liu and Mason 2001,Doyama et al 1996, Hunt et al 2001). Indeed, myocarditis is a 
well-recognized cause of heart failure (Hunt et al 2001). Moreover, there is evidence to suggest 
that some patients with idiopathic dilated cardiomyopathy develop an auto-immune response in 
the myocardium (Luppi et al 1998) and that persistent activation of white cells to produce pro-
inflammatory cytokines, even when assessed ex vivo, may occur in patients with idiopathic 
dilated cardiomyopathy (Aukrust et al 1999, Brooksbank et al 2005a and 2005b). However, 
whether common infections derived from sources other than the myocardium, if repeatedly 
occurring, can produce myocardial damage and dysfunction is a question that has not as yet 
been fully addressed. 
As highlighted in the previous section, relatively low grade inflammation, where the 
inflammation originates as a consequence of heart failure, may be a key determinant of 
progressive heart failure. Thus, it is not unreasonable to hypothesize that low grade 
inflammatory changes derived from sources other than heart failure, may contribute toward 
progressive myocardial damage. Indeed, C-reactive protein, TNF-α, and interleukin-6 (Bahrami 
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et al 2008, Vasan et al 2003, Cesari et al 2003) as well as erythrocyte sedimentation rate 
(Ingelsson et al 2005b), a generalized marker of systemic inflammation, have all been shown to 
be independent predictors of heart failure. However, in these studies (Bahrami et al 2008, 
Vasan et al 2003, Cesari et al 2003, Ingelsson et al 2005b) the source of the inflammatory 
changes was not identified. Whether these inflammatory changes represented the presence of 
low-grade infections derived, for example, from poor dental hygiene causing periodontal disease 
(Moutsopoulos and Madianos 2006, Geerdts et al 2002) or excess adiposity (Ridker et al 2003) 
was not examined. 
There are nevertheless a number of studies to suggest that systemic infections, rather 
than infections of the myocardium per se, promote myocardial damage and dysfunction. In this 
regard, patients with sepsis but without clinical evidence of myocarditis, may have depressed 
cardiac systolic function, in spite of adequate volume resuscitation to correct the reduced 
cardiac filling commonly found in septic shock (Calvin et al 1981, Parker et al 1984, Reilly et al 
1989, Jafri et al 1990, Munt et al 1998, Poelaert et al 1997, Krishnagopalan et al 2002 [review]). 
With respect to the potential mechanisms thereof, there are a number of hypotheses that could 
explain this effect. 
 
3.1 Endotoxin as a myocardial depressant factor 
 
In cases of sepsis, the presence of a “myocardial depressant factor” was proposed more 
than 60 years ago (Wiggers 1947), but it is only recently that potential candidates for this factor 
have emerged. In this regard, infusion of lipopolysaccharide (LPS) (endotoxin), a component of 
the cell wall of gram negative bacteria, has been shown to partially mimic the myocardial and 
systemic cardiovascular effects of sepsis (Suffredini et al 1989, Hung 1993a and 1993b). 
However, because few patients with septic shock have detectable circulating concentrations of 
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LPS (Merx et al 2007) it is unlikely that LPS contributes to the myocardial effects of the majority 
of patients with sepsis. Nevertheless, the concept of LPS mediating decreases in myocardial 
function in septic shock has engendered a notion that LPS could also mediate myocardial 
abnormalities in any gram negative infection irrespective of whether septic shock is present or 
not. 
Over the past two decades, a number of studies have demonstrated that LPS depresses 
myocardial and cardiomyocyte function (Suffredini et al 1989, Brady et al 1992, Hung and Lew 
1993a, 1993b, Tao and McKenna 1994, Nishikawa et al 1995, Nishikawa and Lew 1996, Lew et 
al 1996, 1997a, Stein et al 1996, Yasuda et al 1997a, 1997b, 1999, Tavener et al 2004) and 
induces cardiomyocyte apoptosis (Comstock et al 1998, Li et al 2002, Suzuki et al 2003, 2007, 
McDonald et al 2000, Chagnon et al 2005, Niu et al 2008). However, LPS failed to attenuate 
either baseline cardiomyocyte contractility or noradrenaline-induced increases in cardiomyocyte 
contractility in one study (Muller-Werdan et al 1998). 
Although there is no doubt that a decreased myocardial function contributes toward 
heart failure, there has been some doubt expressed as to the clinical relevance of 
cardiomyocyte apoptosis (programmed cell death). However, there is now increasing evidence 
to indicate that cardiomyocyte apoptosis may be an important change that contributes toward 
cardiac dysfunction and heart failure. In this regard, an increased cardiomyocyte apoptosis 
occurs in transgenic models of heart failure (Sarkar et al 2004) and in human heart failure 
(Abbate et al 2003). Moreover, inhibitors of the caspase enzyme, an enzyme that is central to 
mediating the apoptotic process, have been demonstrated to reduce cardiomyocyte apoptosis 
and attenuate the reduction in left ventricular pump dysfunction in the transition to heart failure 
(Hayakawa et al 2003, Engel et al 2004). Furthermore, implantation of human bone-
marrow−derived angioblasts prevents cardiomyocyte apoptosis and adverse cardiac remodeling 
(Kocher et al 2001). Thus, it appears that cardiomyocyte apoptosis may be a critical determinant 
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of a failing myocardium, and hence that LPS-induced cardiomyocyte apoptosis (Li et al 2002, 
Suzuki et al 2003, Suzuki et al 2007, Comstock et al 1998, McDonald et al 2000, Niu et al 
2008, Chagnon et al 2005) may be a key determinant of heart failure as a consequence of 
severe or repeated systemic infections. Indeed, blockade of a critical enzyme involved in 
apoptosis prevents cardiomyocyte apoptosis and cardiac dysfunction in an animal model of 
sepsis (Neviere et al 2001). 
The potential mechanisms of the LPS-induced decrease in contractile function and 
cardiomyocyte apoptosis have been summarized in Figure 1.2. Importantly, activation of pro-
inflammatory cytokines such as TNF-α may not be a necessary pre-requisite to LPS-induced 
cardiomyocyte apoptosis or contractile dysfunction (Nishikawa et al 1996). The mechanisms of 
the effects are thought to be through LPS-induced effects on Toll-like receptors (Frantz et al 
1999, Tavener et al 2004, Li et al 2002) found either on leukocytes or on cardiomyocytes. LPS-
induced activation of Toll-like receptors on cardiomyocytes is thought to induce apoptosis in-
part by stimulating cardiomyocyte angiotensinogen, and hence through angiotensin II, 
promoting calcineurin-induced cardiomyocyte programmed cell death (Suzuki et al 2007). TNF-
α may however, play a role as LPS-induced apoptosis can be inhibited by administration of a 
TNF-α receptor fragment (Cowan et al 2001, Peng et al 2005). With respect to the mechanisms 
of the LPS-induced decrease in contractile function, this may occur through an impaired 
mitochondrial function (Tavener et al 2004), down-regulation of dihydropyridine receptors (the 
Ca2+ channels required for excitation-contraction coupling in the myocardium)(Lew et al 1996), 
or through the activation of inducible nitric oxide synthase which enhances nitric oxide 
synthesis and produces increases in cardiomyocyte cyclic guanosine monophosphate (cGMP) 
concentrations (Brady et al 1992, Stein et al 1996, Yasuda  and Lew 1997a, 1997b, Lew et al 
1997b, Yasuda and Lew 1999). With respect to the impact of cGMP, in contrast to cyclic 
adenosine monophosphate which promotes contractile function by stimulating 
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Figure 1.2. Potential cellular mechanisms of the deleterious effects of endotoxin on the 
myocardium. LPS, lipopolysaccharide; TLR-4, toll-like receptor-4; Ang II, angiotensin II; AT1 R, 
angiotensin type I receptor. See Figure 1.1 for additional abbreviations. The figure summarises 
pathways supported by the following references: Prabhu et al 2004; Liu et al 2008; Cheng et al 
2009; Suzuki et al 2007;Chagnon et al 2005; Liu et al 2008; Tavener et al 2005.  
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intracellular Ca2+ release from the sarcoplasmic reticulum, cGMP reduces myocardial 
contraction by decreasing the myofilament response to Ca2+. An additional mechanism by which 
LPS induces deleterious effects on the myocardium is through ventricular hypertrophy, which is 
mediated by calcineurin, the release of which was described in the previous paragraphs (Cheng 
et al 2009). 
The now considerable data demonstrating that LPS promotes myocardial dysfunction 
and cardiomyocyte apoptosis (Suffredini et al 1989, Brady et al 1992, Hung and Lew 1993a, 
1993b, Tao and McKenna 1994, Nishikawa et al 1995, Nishikawa and Lew 1996, Lew et al 
1996, 1997a, Stein et al 1996, Comstock et al 1998, Yasuda and Lew 1997a, 1997b, 1999, Li et 
al 2002, Suzuki et al 2003), is of major clinical importance in sepsis and septic shock. Indeed, 
as previously indicated, sepsis and septic shock are frequently associated with a marked 
decrease in cardiac function (Calvin et al 1981, Parker et al 1984, Jafri et al 1990, Munt et al 
1998, Poelaert et al 1997). However, can one extrapolate these data to a potential clinically 
relevant effect in chronic infections or infections which are not associated with the 
haemodynamic changes that accompany sepsis? Obviously it is unlikely that low-grade 
infections result in acute decreases in cardiac contractile or diastolic function and consequently 
cardiac decompensation unless co-existing cardiac pathology exists where febrile responses 
will increase haemodynamic loads on the heart. However, it is also possible that with repeated 
inflammatory responses, modest degrees of cardiomyocyte apoptosis, with no immediate effect 
on heart function, could nevertheless ultimately translate into a significant degree of myocardial 
damage, thus ultimately heralding the onset of cardiac dysfunction and heart failure. 
The authors of the studies showing that cardiomyocyte apoptosis occurs in response to 
LPS (Li et al 2002, Suzuki et al 2003, 2007, Comstock et al 1998) have suggested that this 
effect occurs at sufficiently low enough concentrations of LPS as to be comparable with the LPS 
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concentrations that occur in chronic infections. However, as shall be discussed, there is both 
evidence to support and refute the notion that LPS-induced effects on the myocardium are 
indeed compatible with LPS concentrations that occur during the average chronic infection. 
 
3.2 Is there sufficient evidence to suggest that low grade infections promote 
myocardial damage? 
 
Table 1.1 summarizes all of the studies that to my knowledge have assessed the impact 
of LPS on cardiomyocyte apoptosis conducted in vivo or ex vivo (employing cell cultures). The 
Table also summarizes the doses of LPS employed in the in vivo studies. It should be apparent 
from this Table that the lowest dose of LPS employed by these investigators to produce 
cardiomyocyte apoptosis was I mg/kg (Suzuki et al 2003, Suzuki et al 2007, Li et al 2002). In 
this regard, this dose has recently been reported to produce a marked decrease in blood 
pressure and cerebral vasodilation, an increased circulating lactate concentration, and a 
metabolic acidosis with a compensatory decrease in PaCO2 (respiratory drive) (Rosengarten et 
al 2008). It would thus appear that although increased circulating LPS concentrations occur in 
chronic infections (Moutsopoulos and Madianos 2006, Geerts et al 2002), the lowest dose of 
LPS administered in vivo to induce cardiomyocyte apoptosis (I mg/kg)(Suzuki et al 2003, Suzuki 
et al 2007, Li et al 2002) is more likely to induce all of the changes that one would normally 
consider to be congruent with septic shock (Rosengarten et al 2008). The question therefore 
remains as to whether low-grade infections without the changes associated with septic shock 
are indeed able to produce cardiomyocyte apoptosis. To address this issue, as part of the 
present dissertation I therefore studied the effect of doses of LPS that have previously been 
shown to produce a febrile response consistent with low-grade infections but without producing 
septic shock (Harden et al 2006), on cardiomyocyte apoptosis. 
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Table 1.1. Summary of studies assessing the effects of lipopolysaccharide (LPS) on myocardial apoptosis. 
 
 Author(s) In vivo or in vitro Dose of LPS in  
in vivo studies 
Apoptosis 
               TUNEL              Caspase                  Other 
Suzuki et al 2007 In vivo† 
 
 
1mg/kg Increased between 4-24hr 
(p<0.05) (n=5) 
Increased between 4 and 24hr 
(p<0.05) (n=7-19) 
- 
In vitro† 10ng/ml Increased after 24hr 
 (p<0.05) (n=5-9) 
- - 
Li et al 2002 In vitro† 10ng/ml Increased at 24hr (p<0.01) 
(n=5). 
Increased caspase-3 activity 
at 16hr P<0.05 (n=10) 
Bcl2:bax decreased at 12hr  
(p<0.05) (n=6) 
In vivo† 1mg/kg iv Increased at 1-3 days 
(p<0.05) (n=3) 
- - 
Niu et al 2008 In vivo* 10 mg/kg ip Increased (p<0.01) vs control 
after 12 hours 
No increase in caspase-3/7 
after 12 hours 
- 
Suzuki et al 2003 In vitro† 10ng/ml,24hr Increased after 24hr (p<0.05) 
(n=13) 
- - 
In vivo† 1mg/kg iv Increased after 24 hr (p<0.05)  
(n=5-7) 
- - 
Comstock et al 1998 In vitro 100ng/ml   Comet assay. Increases in percentage 
apoptotic cells (p<0.001) (n=20) 
Chagnon et al 2005 In vivo† 10 mg/kg  Increased caspase-3 (p<0.05) 
after 6hrs and 24hrs 
Increased DNA fragmentation (p<0.05) 
at 6hrs. 
Increased cytochrome-c  (p<0.05) at 
6hrs 
McDonald et al 2000 In vivo†  4mg/kg Increase (p<0.05) at 24hr Increased caspase-3 (p<0.05) 
at 24hrs 
Increased bax (p<0.05) at 24hr. 
Increased bcl2 at (p<0.05) at 6hr 
Chao et al 2005 In vitro† 500ng/ml - Reduced caspase-3 activation 
following serum deprivation.  
LPS reduced histone-DNA 
fragmentation and DNA laddering after 
serum deprivation (p<0.01) (n=3) 
 
† Sprague Dawley rats,*mice 
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4.0 Obesity-induced inflammatory changes and cardiac effects. 
 
As shall be underscored in the present section of the dissertation, obesity is now a well-
recognized source of systemic inflammation. Furthermore, as shall also be highlighted in 
subsequent sections, there is an emerging body of evidence to indicate that obesity produces 
myocardial damage and dysfunction independent of conventional cardiovascular risk factors. As 
there is now a substantial body of evidence to indicate that pro-inflammatory cytokines may 
produce myocardial dysfunction and damage (see section 2.0), it is not inconceivable that 
obesity-induced inflammatory changes may also mediate myocardial damage. Nevertheless, as 
shall be discussed, few studies have pursued the notion that obesity-induced inflammatory 
effects may mediate the adverse effects of obesity on the myocardium. 
The question of the role of inflammation as a potential cause of obesity-induced 
myocardial damage and dysfunction is of importance in the context of the emerging world-wide 
epidemic of obesity. Indeed, the prevalence of obesity is increasing in both developed and in 
economically emerging countries (Ogden et al 2007, Flegal et al 2002, Puoane et al 2002). In 
the United States of America in 2004, ~31% of men and ~33% of women were obese and ~3% 
of men and ~7% of women were extremely obese (a body mass index [BMI] > 40 kg/m2) (Ogden 
et al 2007). In South Africa, a country which is considered to be an emerging economy, at 
approximately the turn of the century, ~29% of men and ~57% of women were obese (Puoane 
et al 2002). 
It may be argued that the solution to this problem is not to identify the mechanisms 
through which obesity produces morbidity and mortality, but rather to focus research efforts on 
weight loss programs. However, there is now increasing evidence to indicate that obesity, once 
established, is difficult to manage. Indeed, weight reduction programs seldom result in obese 
individuals reaching target body weights and frequently result in an inability to maintain 
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appropriate weight reduction (Anderson et al 2001, Klein et al 2004, Lang et al 2006). Thus, 
there is no question that the adverse effects of obesity on the heart and the potential 
mechanisms that explain these effects are of societal importance and of importance to the 
health care sector in South Africa. 
 
4.1 Adipose tissue as a source of inflammation. 
 
As indicated in the aforementioned discussion, one potential mechanism that may 
explain the deleterious effects of obesity on a number of organ systems is through the capacity 
of adipose tissue to increase circulating cytokine concentrations. Indeed, adipose tissue is a key 
determinant of an increased systemic inflammatory state and the evidence for relationships 
between an excess adiposity and the pro-inflammatory mediators C-reactive protein, TNF-α, 
interleukin-6, leptin, and serum amyloid A3 has been extensively reviewed (Berg et al 2005). 
Moreover, although derived from adipocytes, circulating concentrations of the anti-inflammatory 
adipokine, adiponectin, are decreased in obesity (Berg et al 2005). Importantly, reductions in 
circulating concentrations of inflammatory markers are associated with weight loss produced by 
liposuction (Giugliano et al 2004), gastric bypass (Kopp et al 2003) and diet (Heilbronn et al 
2001) and in rats removal of visceral fat reduces TNF-α concentrations (Gabriely et al 2002). Is 
adipose tissue associated with the development of heart failure? 
 
4.2 An excess adiposity is associated with heart failure independent of conventional 
cardiovascular risk factors. 
 
Over the past decade, a nested case-control study and a number of prospective studies 
have demonstrated an independent relationship between the degree of adiposity and the 
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development of heart failure (Chen et al 1999, He et al 2001, Johansson et al 2001, Wilhelmsen 
et al 2001, Kenchaiah et al 2002, 2009, Ingelsson et al 2005a and 2005b, Nicklas et al 2006, 
Bahrami et al 2008, Spies et al 2009). The outcomes and characteristics of these studies have 
been summarized in Table 1.2. This relationship has been demonstrated in the general 
population (He et al 2001, Kenchaiah et al 2002, Ingelsson et al 2005b, Bahrami et al 2008), in 
the middle-aged (Ingelsson et al 2005a), in the elderly (Chen et al 1999, Nicklas et al 2006), in 
men (Wilhelmsen et al 2001, Ingelsson 2005b), in women (He et al 2001), in general practice 
(Johansson et al 2001), in physicians (Kenchaiah et al 2009) and in persons with established 
coronary artery disease (Spies et al 2009). 
As compared to referent body mass indices between 20 and 25 kg/m2, a body mass 
index of between 25 and 30 kg/m2 may increase the risk of heart failure by 39-49% (Bahrami et 
al 2008, Kenchaiah et al 2009) and a body mass index greater than or equal to 30 kg/m2 
increases the risk of heart failure by 83-180% independent of conventional cardiovascular risk 
factors (Johansson et al 2001, Kenchaiah et al 2002, Bahrami et al 2008, Kenchaiah et al 
2009). In one study however, no increased risk for heart failure was noted in persons with a 
body mass index of between 25 and 30 kg/m2 (overweight) in a general practice setting 
(Johansson et al 2001). Moreover, in one study (Spies et al 2009), but not in other studies  
(Ingelsson et al 2005a, Nicklas et al 2006) the adipose tissue-heart failure relationship is better 
predicted by the use of indices of adiposity that reflect an accumulation of fat in central 
(abdominal) stores, such as waist circumference or waist-to-hip ratio, than indices such as body 
mass index. Depending on the study population and the study design, the independent risk for 
heart failure in people whom are overweight or obese is quantitatively comparable with the 
impact of for example the presence of hypertension, or diabetes mellitus in these same studies 
(Table 1.2). 
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Table 1.2. Characteristics and outcomes of studies showing a relationship between an excess adiposity and heart failure. 
Author Sample size Age Follow up  Number of new 
cases 
Relationship between adiposity and heart failure 
After adjustments 
      
      BMI kgm2 
 
   RR (95% CI) 
 
 p value 
Chen et al 
1999 
 
 
1 749 
 
65+ yrs  
 
10 yrs  
 
 
173  
≥28kgm2 
compared with 
BMI <24kgm2.  
1.60 (1.0-2.4) 
 
0.04 
He et al 2001  
 
 
13 643 
5545 men 
8098 women 
 
25-74 
yrs 
 
19 yrs  
 
1 382  
≥ 27.8 kgm2 (men) 
≥27.3kgm2 
(women) 
1.30 (1.12-1.52) 
 
=0.001 
 
Johansson et 
al 2001  
 
689 467 
cases; 
5000 controls 
 
40-84 
yrs 
- 938 (total) 
489 men,  
449 women 
25-29.9kgm2 
 
1.0(0.7-1.2) - 
≥30 kgm2 
 
2.1(1.5-2.8) - 
Kenchaiah et 
al 2002 
 
5 881  
 
 
55 yrs 
 
 
14 yrs 
496 (total)  
238 men  
258 women 
25-29.9kgm2 
 
1.34(1.08-1.67) =0.007 
≥30 kgm2 2.04(1.59-2.63)  <0.001  
Kenchiah et al 
2009 
 
21 094 men 
 
53 yrs 
 
20.5 yrs 
 
1109  
25-29.9kgm2 
 
1.49(1.32-1.69) <0.0001 
≥ 30kgm2 2.80(2.34-3.50) <0.0001 
Ingelsson et 
al 2005a  
 
 
1 187 men 
 
≥70 yrs 
 
7-12 yrs 
 
104  
 1.35 (1.11-1.65) Not shown 
Ingelsson et 
al 2005b  
2 314 men  29.6 yrs 282  1.48(1.33-1.65) <0.001 
Nicklas et al 
2006  
2 435. 
1081 men 
1354 women 
 
70-79 
yrs 
 
6.1 yrs 
166 versus <25 kgm2 
 
1.25(1.02-1.53) p=0.003 
Bahrami et al 
2008  
 
6 814 
55-84 
yrs 
4 yrs 79 versus <25 kgm2          -    - 
Spies et al 
2009 
 
979 
 
65 yrs 
 
4.9 yrs 
128 hospitalised. 
152 cardiovascular 
events 
versus <25 kgm2 
 
1.6 (1.2-2.1)  
Wilhelmson et 
al 2001 
7495 men 47-55 
yrs 
27 yrs 937 ≥30 kgm2 1.06 (1.03-1.09) =0.0001 
 
BMI, body mass index; CHD, coronary heart disease; RR, relative risk. 
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Although the relationship between an excess adiposity and the development of heart 
failure is modified by adjustments for conventional cardiovascular risk factors, including 
hypertension, diabetes mellitus and cholesterol concentrations as well as with adjustments for 
coronary events, the impact of these adjustments is surprisingly modest. Indeed, considering 
overweight and obese persons overall, the percentage risk for heart failure is diminished by only 
1-13% with these adjustments (He et al 2001, Ingelsson et al 2005a, 2005b,  Nicklas et al 2006, 
Spies et al 2009) and by only 55% in obese individuals in a study in which obesity increased the 
risk for heart failure by 180% (Kenchaiah et al 2009). Thus, although there is no question that to 
prevent overweight/obesity-induced heart failure, targeting modifiable cardiovascular risk factors 
with lifestyle interventions and medication is an essential approach, the large residual risk for 
heart failure after adjustments for conventional cardiovascular risk factors indicates that this 
may not be the most appropriate solution. 
 
4.3 Adiposity and cardiac dysfunction 
 
It is important to acknowledge that heart failure is a clinical syndrome with many causes 
that are frequently, but not necessarily directly related to adverse myocardial effects. As such, 
relationships between an excess adiposity and heart failure do not provide direct evidence for 
adverse effects on the heart. Is there evidence to indicate that an excess adiposity is associated 
with adverse cardiac functional changes that could represent an intermediate process in the 
development of heart failure? If so, are there intervention studies with weight reduction to 
provide a proof of principle that an excess adiposity promotes myocardial damage? 
In the Multiethnic Study of Atherosclerosis, the independent relationship between obesity 
and congestive heart failure was reduced from an 83% to a 58% risk of heart failure with the 
inclusion of left ventricular ejection fraction in the regression model (Bahrami et al 2008). These 
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data indicate that decreases in pump function, which in otherwise well individuals is a well 
established risk factor for the development of heart failure (Bahrami et al 2008), is a potentially 
important mechanism through which obesity promotes heart failure. However, not all studies 
support the view that the relationship between an excess adiposity and heart failure can be 
explained by the development of cardiac dysfunction. Indeed, the risk of heart failure that is 
explained by waist-to-hip ratio may persist even with adjustments for measures of cardiac 
function, including ejection fraction and measures of diastolic dysfunction (Spies et al 2009). Is 
there additional evidence to support a view that an excess adiposity may mediate heart failure 
through direct effects on the heart? 
A number of pre-clinical studies have provided evidence to suggest that cardiomyocyte 
dysfunction or damage to the heart may occur in obese states (Caroll et al 1997, Relling et al 
2006, Dong et al 2006, Ren et al 2000, Barouch et al. 2006, Zhou et al 2000). However, as 
many of the animal models employed in these studies (Caroll et al 1997, Relling et al 2006, 
Dong et al 2006, Ren et al 2000, Barouch et al. 2006, Zhou et al 2000) also have associated 
conventional cardiovascular risk factors, whether the outcomes of these studies are indeed 
beyond all conventional risk factors is uncertain. Nevertheless, in human studies, load-
independent tissue Doppler indices of both systolic and diastolic myocardial function have been 
shown to be reduced in overweight and obese people without conventional cardiovascular risk 
factors (Peterson et al 2004, Wong et al 2004). Further, at a population level, indices of excess 
adiposity are independently and inversely related to diastolic chamber function beyond a 
number of conventional cardiovascular risk factors (Redfield et al 2003, Ammar et al 2008, 
Fischer et al 2003, Tsioufis et al 2009, Libhaber et al 2009) including blood glucose control as 
determined from glycated haemoglobin measurements, ambulatory blood pressure and arterial 
stiffness (Libhaber et al 2009). In contrast, the independent relationship between an excess 
adiposity and systolic chamber function is controversial, with some studies showing a 
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relationship between an excess adiposity and systolic function (Ammar et al 2008, Chinali et al 
2006, Peterson et al 2004, Wong et al 2004, Scaglione et al 1992, Karason et al 1998, Alpert et 
al 1995, Alpert et al 1993), whilst others have failed to do so (Pascual et al 2003, de Devitiis et 
al 1981, Zarich et al 1991, Stoddard et al 1992, De Simone et al 1996, Mureddu et al 1996, 
Iacobellis et al 2002). 
More direct evidence to support a role for an excess adiposity in producing cardiac 
dysfunction is that obtained from studies of weight reduction. Weight loss induced either by 
gastric bypass surgery (Willens et al 2005, Rider et al 2009) or by lifestyle intervention (Wong et 
al 2006) results in improvements in myocardial diastolic function independent of conventional 
cardiovascular risk factors. However, even with the use of load-independent tissue Doppler 
measures of myocardial as opposed to chamber function, or with chamber function 
assessments, weight loss produced by either lifestyle modification or gastric bypass does not 
influence left ventricular systolic function (Willens et al 2005, Rider et al 2009, Wong et al 2006, 
Skilton et al 2007). The ability of gastric bypass surgery to improve myocardial diastolic function 
(Willens et al 2005, Rider et al 2009) independent of conventional cardiovascular risk factors 
and in association with weight loss, nevertheless provides more convincing evidence for a role 
of obesity in promoting heart failure through direct effects on the heart. Furthermore, as weight 
loss following gastric bypass surgery avoids the use of dietary interventions, this evidence 
(Willens et al 2005, Rider et al 2009) suggests that obesity rather than dietary constituents 
contribute toward this beneficial effect of weight loss on the heart. 
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4.3 Is there a relationship between an excess adiposity and cardiac dysfunction 
beyond all potential haemodynamic mediators? 
 
There are a number of potential hypotheses to explain the relationship between obesity 
and myocardial damage or dysfunction independent of conventional cardiovascular risk factors. 
Before I discuss the potential role of inflammatory substances derived from adipose tissue as 
determinants of obesity-cardiac dysfunction relations, it is important that I first exclude a role for 
haemodynamic factors that are not normally measured as part of risk assessment. In this 
regard, a number of haemodynamic factors may mediate obesity-induced decreases in cardiac 
systolic or diastolic function. These haemodynamic factors include the following: 
A decrease in total peripheral resistance with a subsequent increase in venous return 
may occur in obese people, an alteration that may increase volume preloads on the heart 
(Messerli et al 1983, Carabello and Gittens 1987). Furthermore, an increase in large artery 
stiffness is associated with an excess adiposity (Sutton-Tyrrell et al 2001, Majane et al 2008), a 
change that may increase central blood pressure by promoting earlier wave reflections. Hence, 
there is a possibility that an enhanced cardiac afterload may occur in people with an excess 
adiposity, mediated by changes in central as opposed to peripheral arteries. Measurements of 
peripheral blood pressures may not reveal these increases in central pressures because of the 
effects of pressure amplification that occurs from central to peripheral arteries. Last, the 
relationship between an excess adiposity and 24 hour blood pressures may not be the same as 
that between an excess adiposity and office blood pressures (Majane et al 2007). Thus, 
measurements of office blood pressure may not reveal the full extent of obesity-induced 
increases in blood pressure on the heart. 
Is there evidence to indicate that an excess adiposity promotes cardiac dysfunction 
beyond all of the aforementioned haemodynamic changes? Indeed, at a community level, the 
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independent relationship between central obesity and a reduction in left ventricular chamber 
diastolic function is independent of left ventricular filling volumes, large artery stiffness and 24-
hour ambulatory blood pressure (Libhaber et al 2009). Consequently, a potential role of non-
haemodynamic factors mediating obesity-induced decreases in cardiac dysfunction requires 
consideration. 
 
4.4 Obesity-induced inflammation as a potential determinant of cardiac dysfunction. 
 
There are a number of hypotheses that could potentially explain the independent 
relationship between obesity and either heart failure or decreases in cardiac systolic or diastolic 
function. However, with respect to the topic of the present dissertation, I will restrict the 
discussion to the hypothesis that inflammatory mediators derived from adipose tissue may 
explain this relationship. Before discussing the evidence to suggest that obesity-derived 
inflammatory changes mediate heart failure, it is nevertheless important to highlight the fact that 
C-reactive protein, TNF-α, and interleukin-6 (Bahrami et al 2008, Vasan et al 2003, Cesari et al 
2003) as well as erythrocyte sedimentation rate (Ingelsson et al 2005b), a generalized marker of 
systemic inflammation, have all been shown to be independent predictors of heart failure. 
In support of a role for obesity-derived inflammatory substances as mediators of heart 
failure, after adjustments for either interleukin-6 or C-reactive protein in the regression analysis, 
the independent relationship between obesity and heart failure failed to achieve statistical 
significance (Bahrami et al 2008). However, in that study (Bahrami et al 2008) the increased risk 
for heart failure in obese patients decreased from an 83% risk (hazards ratio=1.83) to a 50-58% 
risk (hazards ratio=1.50-1.58) after adjustments for inflammatory markers. Thus, a potential 
residual risk for heart failure remained even after adjustments for pro-inflammatory markers 
(Bahrami et al 2008). In support of this notion, in another study (Spies et al 2009), the 
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independent relationship between waist-to-hip ratio and the subsequent development of heart 
failure in patients with established coronary artery disease was only partially modified with 
adjustments for C-reactive protein (CRP), TNF-α, and interleukin-6. In that study, the 
independent relationship between an excess adiposity and the development of heart failure 
remained even after adjustments for these inflammatory markers (Spies et al 2009). Thus, there 
is still considerable controversy as to the role of adipose tissue-derived pro-inflammatory 
substances in the development of obesity-induced heart failure. Is there evidence for a role of 
anti-inflammatory substances derived from adipose tissue as possibly mediating protective 
effects on the myocardium? 
Pre-clinical studies suggest that the adipose tissue-derived anti-inflammatory substance 
adiponectin protects the heart against adverse myocardial effects. Indeed, adiponectin knock-
out promotes (Shibata et al 2004, Sam et al 2010) and delivery of adiponectin attenuates 
(Shibata et al 2004) adverse cardiac remodelling in response to a pressure overload. 
Furthermore, adiponectin knock-out augments diastolic dysfunction and promotes the 
development of diastolic heart failure in pressure overload states (Sam et al 2010). However, 
prospective studies have failed to show adiponectin as an independent risk factor for the 
development of heart failure (Ingelsson et al 2006, Frankel et al 2009). 
 
4.4 Further work is required to explore the role of inflammation as a determinant for 
the impact of obesity on the myocardium. 
 
Clearly further evidence is still required to identify whether increased concentrations of 
pro-inflammatory substances and decreased concentrations of anti-inflammatory substances 
mediate the independent relationship between obesity and cardiac failure and dysfunction. As 
there are presently only two studies to-date that have explored whether an excess cytokine 
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production contributes toward obesity-induced heart failure (Kenchaiah et al 2002, Spies et al 
2009), there is an obvious need to pursue this question further. In this regard, both animal and 
human studies are required to either support or refute this notion. 
Human studies are required to assess whether the relationship between obesity and 
cardiac dysfunction or the beneficial impact of weight reduction on cardiac function can be 
accounted for by the presence of circulating inflammatory markers. Animal studies are required 
to inhibit cytokine production in models of obesity and determine whether this improves cardiac 
function. In our laboratory, although we have access to an animal model of dietary-induced 
obesity, members of our group have recently demonstrated that this model is not associated 
with left ventricular systolic dysfunction (du Toit et al 2008). Therefore, this is not a model which 
can be employed to determine the mechanisms of obesity-induced systolic dysfunction. 
In contrast, our laboratory is studying left ventricular structure and function in a 
community-based sample with a high prevalence of obesity (Norton et al 2008, 2009, 
Woodiwiss et al 2008, 2009, Majane et al 2007, 2008). Consequently, as part of the present 
dissertation, I explored the possibility that a marker of inflammation, CRP, may in-part explain 
the association between an excess adiposity and left ventricular systolic dysfunction in a 
relatively large population sample obtained from an ongoing study being conducted in an urban, 
developing community of African ancestry with a high prevalence of obesity (Norton et al 2008, 
2009, Woodiwiss et al 2008, 2009, Majane et al 2007, 2008). 
To evaluate the impact of CRP on systolic cardiac function, I selected to assess the 
relationship between CRP and cardiac function in a community sample, as compared to a 
sample of patients in heart failure. I employed this approach to dissect out the effect of “obesity-
mediated” as compared to “heart failure-mediated” inflammatory-induced changes (see previous 
sections). However, there is some controversy as to the method of assessing cardiac systolic 
function in studies where heart failure is not present. Therefore, before describing the studies 
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performed as part of the present dissertation, it is important that I first outline the controversies 
regarding the detection of preclinical abnormalities of systolic cardiac function in human studies. 
 
5.0 The detection of an abnormal systolic cardiac function in human studies of 
obesity 
 
A number of studies have been conducted to assess the relationship between obesity 
and cardiac function in human studies. In this regard, the majority of studies have reported on a 
deleterious effect of obesity on diastolic function of the heart, but studies assessing the impact 
of obesity on systolic chamber function (pump function) independent of conventional 
cardiovascular risk factors have produced conflicting outcomes with the majority showing a lack 
of effect of obesity on cardiac pump function as indexed by left ventricular ejection fraction or 
other measures of chamber function (Peterson et al 2004, Wong et al 2004, Pascual et al 2003, 
Scaglione et al 1992, de Devitiis et al 1981, Chakko 1991, Zarich et al 1991, Stoddard et al 
1992, De Simone et al 1996, Mureddu et al 1996, Iacobellis et al 2002, Karason et al 1998). 
Nevertheless, subsequent studies performed using tissue Doppler imaging techniques, which 
assess myocardial function, have demonstrated a reduction in myocardial systolic function in 
obesity, despite a normal systolic chamber function (Peterson et al 2004, Wong et al 2004).  
Although I did not have access to tissue Doppler imaging techniques for the assessment 
of myocardial function, one measure of myocardial function that has not previously been 
explored with respect to a potential impact of obesity independent of hypertension, is left 
ventricular midwall fractional shortening. In contrast to left ventricular endocardial fractional 
shortening, which is an index of systolic chamber function, left ventricular midwall fractional 
shortening is an assessment of myocardial function (Norton et al 2002). A number of studies 
have now demonstrated that under circumstances of a normal systolic chamber function, as 
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indexed by endocardial fractional shortening, when the left ventricle is concentrically 
remodelled, midwall fractional shortening may be reduced (Mayet et al 2002,De Simone et al 
1994, Li et al 2001,Muiesan et al 2000). Although a lack of relationship between body size and 
left ventricular midwall fractional shortening has been reported on in hypertensives (De Simone 
et al 1996), this relationship has not been studied in the absence of the confounding effects of 
hypertension (i.e, in the general population). Moreover, this relationship has not been assessed 
in a population sample with a high prevalence of obesity or in a population sample with a high 
prevalence of concentric cardiac remodelling produced by an excess adiposity.  As we have 
recently demonstrated that obesity produces marked concentric remodelling of the left ventricle 
(Woodiwiss et al 2008), the use of midwall fractional shortening to assess the relationship 
between obesity and cardiac systolic function is entirely appropriate. 
Therefore, in the present dissertation I evaluated the relationship between CRP and left 
ventricular midwall fractional shortening, in a relatively large population sample obtained from 
an ongoing study being conducted in an urban, developing community of African ancestry with a 
high prevalence of obesity. 
 
6.0 Summary of problem statements 
 
Problem statement 1: Although there is evidence to indicate that LPS, derived from gram 
negative organisms, can promote cardiomyocyte apoptosis, there is a question as to whether 
the doses of LPS employed in these studies produce effects that represent septic shock or low-
grade infections. 
Problem statement 2: Although there is evidence to indicate that obesity can promote 
cardiac dysfunction independent of conventional cardiovascular risk factors, only two studies 
have explored whether a relationship with heart failure could be mediated by inflammatory 
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changes associated with obesity and no studies have assessed whether an independent 
relationship with cardiac dysfunction could be mediated by inflammatory changes associated 
with obesity. 
 
7.0 Aims of the dissertation 
 
The major aim of the present dissertation was to provide further proof of principle that 
low grade inflammation may contribute toward myocardial damage and dysfunction. In this 
regard the specific aims of the present dissertation were: 
 
1) To assess whether pyrogenic, but not septic doses of LPS promote cardiomyocyte 
apoptosis in rats. 
2) To determine whether indices of adiposity are independently associated with left 
ventricular midwall as opposed to endocardial fractional shortening in a randomly 
selected community sample with a high prevalence of excess adiposity and 
subsequently to evaluate whether this relationship could be accounted for by circulating 
concentrations of the inflammatory marker, CRP.   
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As indicated in chapter 1, in the present dissertation, two separate studies were 
conducted, one in rats and one in a cross-sectional population sample. The justification for 
using rats in one study and humans in another has already been provided. For ease of reading, 
the methodology for these two studies will be described in separate sections. 
   
2.1 Methodology for the study to assess whether pyrogenic doses of LPS promote 
cardiomyocyte apoptosis in rats. 
 
2.1.1 Study design and animals 
  
Male Sprague-Dawley rats weighing between 400g and 500g were studied. Rats were 
housed individually in cages where the room temperature was maintained at approximately 
22ºC and the lighting set to a 12:12 hour light: dark cycle. Food and water were provided ad 
libitum. Rats were handled and injected with saline daily at the volume employed to administer 
LPS (1ml/kg) for a period of two weeks prior to the study to habituate them to the experimental 
procedures. The habituation took place to prevent stress-induced hyperthermia, which 
commonly results from novel handling procedures (Kluger et al 1987,Cabanac et al 1992). 
To assess the effects of a pyrogenic dose of lipopolysaccharide (LPS) on the heart, rats 
were randomly assigned to receive a subcutaneous injection of either saline (1 ml/kg) or 
Lipopolysaccharide (LPS) (250 µg/kg). The LPS was derived from Escherichia coli endotoxin 
(serotype 0111:B4, Sigma, St. Louis, MO, USA) and reconstituted with saline (sterile, pyrogen-
free 0.9% saline, Sabax, Johannesburg, South Africa). A stock solution of 5000µg/ml was 
prepared and diluted to a concentration of 250µg/ml. As LPS is present in the environment, 
sterility was maintained in the procedures involving preparation of the stock solution. It has 
previously been documented that LPS adheres to plastic whilst in storage, and therefore the 
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stock solution was prepared specifically with the aim of standardizing the concentration of the 
solution contained therein. Tubes containing LPS were placed in an ultrasonic bath which 
removed any LPS adherent to the tube. LPS or saline were injected subcutaneously (Harden et 
al 2006) on two separate, consecutive  days and the second LPS injection was exactly 24hour 
after the first injection for each rat. The rats were killed 6 hours after the second LPS injection. 
Two LPS injections were given to ensure that cardiomyocyte apoptosis was assessed at the 
time of a febrile response (second injection), but also following a sufficiently long period to 
ensure that apoptotic cell death could be detected using a TUNEL system. The LPS was 
administered at approximately the same time of the day in each rat (between 7 and 9am), to 
eliminate the possible effect of circadian alterations in temperature, which could possibly affect 
the amplitude of the fever response. 
Rats were anaesthetized 6 hours after the second injection of LPS or the vehicle in order 
to perform echocardiography. Echocardiography was performed to exclude the possibility that a 
sufficiently large dose of LPS was administered to produce myocardial dysfunction and could 
therefore be considered to produce haemodynamic changes consistent with sepsis. The hearts 
were then rapidly removed under anaesthesia and placed in ice cold water, dissected and 
stored in 10% phosphate buffered formaldehyde for histological assessments (for the evaluation  
of cardiomoycyte apoptosis). 
To evaluate the pyrogenic effect of the LPS, febrile responses to LPS or the saline 
vehicle were determined in a separate group of 10 rats using temperature-sensitive 
radiotransmitters.The dose of LPS administered to rats was considered physiologically effective 
if a fever developed. A fever was defined as an increase in core body temperature above 1°C. 
 
35 
 
2.1.2 Core body temperature measurements and assessment of fever responses 
 
Core body temperature was measured continuously and in real-time using surgically 
implanted, temperature-sensitive radiotransmitters (resolution: 2ºC, Data Sciences) (Figure 2.1) 
implanted into the peritoneal cavity of rats. One radiotransmitter was surgically implanted into 
each rat, following the induction of anaesthesia with a combination of xylazine (4mg/kg 
intramuscularly) and ketamine hydrochloride (80mg/kg intramuscularly). The radiotransmitters 
were coated in non-toxic plastic which reduced the risk of infection and the extent of tissue 
adhesion, both of which could influence the accuracy of the results. Core body temperature was 
measured by the temperature-sensitive radiotransmitters which employ remote biotelemetry. 
The output frequency (Hz) of the transmitter was monitored at 5 minute intervals by a receiver 
plate (RTA 500, Mini-Mitter, Sunriver, OR, USA) below the cage of each rat (figure 2.1, bottom 
panel). The frequency transmitted by each plate was fed into a peripheral processor (DP-24 
Data-Port, VitalView, Minimitter, Sunriver, OR, USA) connected to a personal computer and the 
output was measured in degrees centigrade. Rats were allowed to recover for two weeks 
following the surgery before the effect of LPS was determined. 
To obtain average daily temperatures, the temperature over time was calculated as the 
area under the graph of a time-temperature graph (Figure 2.2). To ensure that the increase in 
core body temperature following LPS administration was a true reflection of a fever, and not a 
result of daily fluctuations in core body temperature during the circadian rhythm, the average 
area under the curve (thermal response index) was calculated for each rat over a period of three 
days prior to LPS or vehicle administration. The difference between the thermal response index 
following LPS or vehicle administration and the average daily temperature obtained from the 
average area under the graph over 3 days prior to either LPS or saline administration was 
assessed. 
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Figure 2.1. Photograph of the surgically implanted, temperature-sensitive radiotransmitter used 
to determine core body temperature (top). The bottom panel shows the recording plate placed 
underneath the cage that an individual rat was housed in, as illustrated by the arrow.  
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Figure 2.2. Method of assessing the magnitude of a fever. The area under curve for the typical 
core body circadian rhythm fluctuation in temperature (grey) is subtracted from the area under 
the curve for the core body temperature response to lipopolysaccharide (LPS) (vertical lines) 
administration. Data shown are obtained from a single animal. 
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2.1.3 Cardiac structure and function in rats 
 
To determine the impact of LPS on left ventricular dimensions and systolic chamber or 
myocardial function in anaesthetized rats, echocardiography was performed using previously 
described methods (Norton et al 2002, Woodiwiss et al 2001). To perform echocardiography 
rats were anaesthetized with 50mg/kg of ketamine and 3mg/kg of xylazine to ensure immobility 
during the procedure. A high resolution ultrasonic probe (7 MHz paediatric probe) was used to 
obtain two-dimensional guided M-mode images of the rat left ventricle using an approach 
previously described (Chung et al 1998, Norton et al 2002) (Figure 2.3) on an Accuson 
echocardiograph. Care was taken to ensure that an M-mode image was obtained at the level of 
the papillary muscles. As the right ventricular cavity was difficult to visualize, septal wall 
thickness values were not determined. However, left ventricular end diastolic and end systolic 
internal diameter and posterior wall thickness values were determined (Figure 2.3). Left 
ventricular internal dimensions during systole and diastole were measured using the American 
Society for Echocardiography's (Sahn et al 1978) leading edge method (Norton et al 2002). 
Measurements were made from 3 consecutive beats. Left ventricular chamber and myocardial 
systolic function were determined from endocardial (FSend) and midwall (FSmid) fractional 
shortening respectively, as previously described (Norton et al 2002) using the following 
equations: 
FSend = (EDD-ESD/EDD) x 100 
FSmid = [(EDD+ED PWT)/2-(ESD+ES PWT)/2]      x 100 
                  (EDD+ED PWT)/2 
where EDD = end diastolic diameter, ESD = end systolic diameter, ED PWT = end diastolic 
posterior wall thickness and ES PWT = end systolic posterior wall thickness. 
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Figure 2.3. A representative M-mode image used to determine left ventricular structure and 
function in rats.  EDD, end diastolic diameter; ESD, end systolic diameter; PWTd, posterior wall 
thickness at the end of diastole; PWTs, posterior wall thickness at the end of systole.  
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The calculation of midwall diameter at either end diastole or end systole is based on an 
assumption that PWT = septal wall thickness, and hence that half of PWT = half of septal wall 
thickness.  
 
2.1.4 Assessment of cardiomyocyte apoptosis. 
 
After removal of the heart from the thoracic cavity under anaesthesia, the heart was 
placed in ice cold water, weighed, dissected and stored in 10% phosphate buffered 
formaldehyde for a maximum period of 24-hours. Myocardial tissue was subsequently 
processed and embedded in paraffin wax. The degree of apoptosis was quantified on 5µm thick 
tissue sections. Nuclear deoxyribonucleic acid (DNA) fragments in the tissue sections were 
detected using a non-radioactive in situ apoptotic cell death detection kit (DeadEndTM 
Colorimetric TUNEL system, Promega, Madison, WI, USA), where terminal deoxynucleotidyl 
transferase (TdT) was used to incorporate biotinylated nucleotide at the 3’-OH DNA ends. 
Horseradish-peroxidase-labeled streptavidin binds to biotinylated nucleotides, which 
subsequently stain dark brown in response to hydrogen peroxide and diaminobenzidine 
(Agarwala and Kalil, 1998). Both positive (DNase treated) and negative (no addition of TdT) 
control tissue sections were incorporated into each assay. 
Paraffin embedded sections were first immersed in xylene for 5 minutes to de-paraffinize 
the tissue sections. The tissue sections were then washed by immersing the slides in 100% 
ethanol for 5 minutes and again for 3 minutes. The sections were rehydrated in graded ethanol 
washes (95%, 85%, 70% and 50%) for 3 minutes each. The slides were washed in a 0.85% 
NaCl solution for 5 minutes and in phosphate buffered saline for 5 minutes. The tissue sections 
were fixed by immersing the slides in a 4% paraformaldehyde solution for 15 minutes and the 
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slides were then immersed in phosphate buffered saline for 5 minutes, dried, and placed on a 
flat surface. 
To increase the permeability of the cell membrane, 100µl of a 20µg/ml proteinase K 
solution was added to the slides to cover each tissue section and incubated for 30 minutes at 
room temperature. The tissue sections were washed by immersing the slides in phosphate 
buffered saline for 5 minutes and re-fixed by immersing in a 4% paraformaldehyde solution and 
washed again in phosphate buffered saline for 5 minutes. At this point the positive control slide 
was treated with DNase I to cause DNA fragmentation whilst the experimental slides remained 
in a phosphate buffered saline solution. 100µl of DNase I buffer was added to the positive 
control slide to cover the tissue sections and incubated at room temperature for 5 minutes. 
DNase I buffer containing DNase was added to cover the tissue sections and the slides were 
incubated for 10 minutes at room temperature. The positive control slide was washed 4 times in 
distilled water and in phosphate buffered saline for 5 minutes. 
The tissue sections were covered with equilibration buffer for 8 minutes. 10µl of 
biotinylated nucleotide mix and 10µl of rTDT Enzyme were added to 980µl of equilibration buffer 
for the reaction mix. A control incubation buffer was prepared for the negative control slide by 
adding 1µl of biotinylated nucleotide mix and 1µl of distilled water to 98µl of equilibration buffer. 
After equilibration the slides were blotted with tissue paper to remove excess liquid and 100µl of 
the rTDT reaction mix was then added to each tissue section. The sections were covered with 
plastic cover slips and incubated at 37˚C for 60 minutes inside a humidified chamber to allow 
the end-labeling reaction to occur. After 60 minutes the slides were removed from the incubator 
and the plastic cover slips removed. 20X SSC was diluted with distilled water and the rTDT 
reaction terminated by immersing the slides in 20X SSC solution for 15 minutes. The tissue 
sections were subsequently washed in phosphate buffered saline twice for 5 minutes each to 
remove unincorporated biotinylated nucleotides. The slides were immersed in 0.3% hydrogen 
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peroxide for 5 minutes to block the endogenous peroxides and washed with phosphate buffered 
saline for 5 minutes. 
Streptavidin horseradish peroxidase was diluted in phosphate buffered saline and 100µl 
was added to each slide to cover the tissue sections. The slides were incubated at room 
temperature for 30 minutes and washed with phosphate buffered saline for 5 minutes. 50µl of 
DAB Substrate 20X Buffer, 50µl of DAB 20X Chromogen and 50µl of Hydrogen Peroxide 20X 
were added to 950µl of distilled water. 100µl of the DAB solution was then added to each slide 
to cover the tissue sections for 8 minutes at room temperature. The slides were rinsed 4 times 
with distilled water, dehydrated by immersing the slides in graded ethanol washes (50%, 70%, 
85% and 95%) and immersed in xylene. The slides were subsequently mounted using 
permanent mounting medium. 
The number of apoptotic cardiomyocyte nuclei and the total number of cardiomyocyte 
nuclei (haematoxylin and eosin stain) in each slide were counted on ten evenly spaced fields 
from the apex to the base using a computer-based image acquisition and analysis system at 
400 times magnification (Axiovision 3, Carl Zeiss, Gottingen, Germany). Apoptotic 
cardiomyocyte nuclei were expressed as a percentage of the total number of cardiomyocyte 
nuclei. Representative examples of stained sections for the samples assessed and from positive 
and negative controls are illustrated in Figure 2.4. All sections were coded and a single observer 
“blinded” to the identity of the rat from which the section was obtained recorded the number of 
apoptotic nuclei, and counted the total number of cardiac myocyte nuclei from the haemotoxylin 
and eosin slides. 
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Figure 2.4. Histological sections of the myocardium stained for apoptotic nuclei. The upper 
panels illustrate sections obtained from a positive (left) and a negative (right) control and the 
lower panel a section from the myocardium of a heart showing one apoptotic cardiomyocyte 
nucleus (arrow). Note the numerous apoptotic nuclei in the positive control section. 
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2.2  Methodology for the study to assess whether inflammation in-part explains the 
relationship between obesity and myocardial dysfunction. 
 
2.2.1 Study participants 
 
The study protocol was approved by the University of the Witwatersrand Committee for 
Research in Human Subjects (approval number: M02-04-72 and renewed as M07-04-69). 
Participants of African ancestry, with a minimum age for participation being 16 years, but 
without an upper age limit, were recruited from nuclear families of the South-Western township 
(Soweto) of Johannesburg. A lower age limit was included as BP rapidly increases with age 
below this value. Random recruitment of spouses and siblings living in households from formal 
dwellings represented in the last census conducted (2001) was performed. Street names and 
addresses of households with at least one parent and two siblings or two parents and one 
sibling were obtained from the Department of Home Affairs. These households were allocated 
numbers and numbers were selected from a random number generator. People residing in 
informal dwellings or institutions/homes were not recruited. 
Recruitment for the present study was initiated in October 2003 and data obtained up 
until November 2006 were used for the present dissertation. Up until November 2006, of the 
1082 participants that were invited to be part of the study, 671 (62%) agreed to participate. Of 
the 671 participants enrolled, 418 (62%) agreed to echocardiograph assessments. Of these, 
data from 19 were discarded because of poor quality echocardiograph assessments and 16 
participants had insufficient serum to assess CRP concentrations. As cardiac function is 
influenced by antihypertensive therapy, analysis was restricted in participants who were not 
receiving treatment for hypertension. Thus, in total, data from 292 participants were assessed in 
this study. 199 (68%) of the participants recruited were of the Nguni chiefdom (Zulu, Xhosa, 
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Ndebele, Swati) and 93 (32%) were of the Sotho chiefdom (South Sotho, North Sotho and 
Tswana). The lack of representation from the Venda chiefdom reflects a lack of individuals of 
this chiefdom residing in these areas of Johannesburg. No participants of mixed, Asian, or 
European ancestry were recruited and no Khoi-San subjects were recruited. All participants 
gave written, informed consent to participate in the study. 
 
2.2.2 Questionnaire 
 
Participants completed a standard questionnaire, where in order to avoid translational 
errors, the questionnaire was not translated into an African language, but study assistants 
familiar with all languages spoken in these townships and who either previously lived in Soweto 
or currently reside in Soweto assisted with the completion of each questionnaire. Only same sex 
assistants were used to assist each family member with the completion of the questionnaire. 
Assistance was only provided when requested. The majority of participants were reasonably 
proficient in English. Study assistants first visited homes of participants in order to develop a 
trusting relationship. The questionnaire was only completed at a subsequent clinic visit and then 
ambiguities checked by performing a follow-up home visit. If family members were absent at 
follow-up home visits, data was checked with them personally via telephonic conversations 
whenever possible. Ambiguities in answers to the questionnaire were detected by an 
independent observer prior to the second home visit. A pilot study was conducted in 20 subjects 
to ensure that data obtained in the questionnaires were reproducible when obtained with the 
assistance of two separate study assistants. 
The questionnaire requested specific answers to date of birth, gender, previous medical 
history, the presence of hypertension, diabetes mellitus and kidney disease, prior and current 
drug therapy (analgesic use included), prior and current occupation, level of education, smoking 
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status (including the number of cigarettes smoked in the past and at the present time), daily 
alcohol consumption (beer, traditional beer or other forms of alcohol and the daily quantity), 
caffeine consumption (number of cups of tea or coffee and whether they are decaffeinated and 
the number of cola’s a day), exercise frequency and family history of hypertension and 
cardiovascular events. For females, menstrual history, history of pregnancies and oral 
contraceptive use was evaluated. Most of the questions simply required a “Yes”-“no” answer, 
but understanding was assessed by requesting some short answers. If subjects were unable to 
provide the name of medication taken these were obtained on the second home visit. Although 
information on education, present occupation and annual incomes were obtained, these data 
have not been analysed at this point as an appropriate score has not been derived. 
 
2.2.3 Blood pressure, pulse rate and anthropometric measurements and blood tests 
 
Trained nurse-technicians measured blood pressure using a standard mercury 
sphygmomanometer during a clinic visit. A standard cuff with a 12 × 24 cm inflatable bladder 
was used, but if upper arm circumference exceeded 31 cm, larger cuffs with a 15 × 35 cm 
inflatable bladder were used. After 10 minutes of rest in the seated position, five consecutive 
blood pressure readings were taken 30 to 60 seconds apart, followed by a pulse rate count. The 
cuff was deflated at approximately 2 mm Hg per second and phase I (systolic) and phase V 
(diastolic) blood pressure recorded to the nearest 2 mm Hg according to the recommendations 
of the European Society of Hypertension (O’Brien et al 2003). The average of the five readings 
was taken as the clinic blood pressure. In the present study quality control of blood pressure 
assessments was assessed as previously described (Majane et al 2007). Only 0.68% of visits 
had fewer than the planned blood pressure recordings. The frequency of identical consecutive 
recordings was 0% for systolic blood pressure and 0% for diastolic blood pressure. The 
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occurrence of blood pressure values recorded as an odd number was 0%. Of the 2912 systolic 
and diastolic blood pressure readings, 28.8% ended on a zero (expected =20%). A diagnosis of 
hypertension was made if subjects were receiving antihypertensive therapy and/or if the 
average of the mean values for the clinic readings was ≥140/90 mm Hg. 
Body height, weight, waist and hip circumference and triceps and subscapular skin-fold 
thickness (Harpenden Skinfold Calliper, Bedfordshire, UK) were measured during the clinic visit 
by a trained observer. Height and weight were measured with the participants standing and 
wearing indoor clothes with no shoes. Waist circumference (WC) and hip circumference were 
measured according to conventional techniques (World Health Organisation, 2000). Body mass 
index (BMI) was calculated as weight in kilograms divided by the square of height in meters and 
waist-to-hip ratio calculated as an index of central obesity. Mean skin-fold thickness was 
calculated as the mean of sub-scapular and triceps skin-fold thickness values. Participants were 
identified as being overweight if their BMI was ≥25 kg/m2 and obese if their BMI was ≥30 kg/m2. 
Central obesity was defined as an enlarged WC (≥88 cm in women and ≥102 cm in men). 
 Blood samples were obtained on the day of the clinic visit and sent to the South African 
National Health Systems Laboratories to perform a full blood count and differential count, to 
measure urea, creatinine and electrolyte concentrations, to assess liver function (from alanine 
transaminase, aspartate transaminase, gamma gluteryl transaminase, alkaline phosphatase, 
albumin, total protein and plasma albumin,  total bilirubin, and conjugated and unconjugated 
bilirubin concentrations) and plasma urate concentrations, to obtain a lipid profile (total 
cholesterol, low density lipoprotein cholesterol concentrations, high density lipoprotein 
cholesterol concentrations and triglyceride concentrations), a blood glucose measurement, 
percentage glycated haemoglobin (HbA1c) (Roche Diagnostics, Mannheim, Germany) and a 
follicle stimulating hormone concentration in females (to confirm menopausal status in females). 
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Diabetes mellitus or abnormal blood glucose control was defined as the use of insulin or oral 
hypoglycaemic agents or a glycated haemoglobin value greater than 6.1% (Bennett et al 2007). 
 Serum C-reactive protein (CRP) concentrations were measured using a quantitative 
immunoturbidimetric assay (Kit 6K2602, Architect, Sentinel Diagnostics, USA) which employs 
an method of detection with the lowest detection limit being 0.01 mg/dl. The analysis was 
performed on an Olympus OSR 6185 (Olympus Diagnostics, Lismeehan, Ireland) with inter- and 
intra-assay coefficients of variation of 1.3% and 0.4%, respectively. In this assay serum 
containing CRP agglutinates when it comes into contact with polyclonal anti-CRP antigens 
bound to latex particles in a 0.2% suspension. Once CRP and anti-CRP have agglutinated, the 
concentration of CRP is determined by spectrophotometry, as assessed by an absorbance 
change from an initial 572 nm. The lowest detection limit of the CRP assay of 0.01 mg/dl is 
lower than that for the high-sensitivity CRP assay of 0.02 mg/dl. Samples with concentrations 
that exceeded the upper limit were diluted at a ratio of 1:10 with normal saline and re-analyzed. 
The presence of a generalized systemic infection was diagnosed if CRP concentrations were 
≥10 mg/dl. 
 
2.2.4 Echocardiography in human participants 
 
Echocardiographic measurements were performed by an experienced observer using a 
pulse colour Doppler Hewlett Packard model 4500-5500 recorder coupled to a 2.5 MHz 
transducer. Left ventricular dimensions were determined using two-dimensional directed M-
mode echocardiography in the short axis view and these recordings analyzed according to the 
American Society of Echocardiography convention (Sahn et al 1978). During recordings, the 
transducer was placed perpendicular to the chest wall or pointed slightly inferiorly and laterally 
at the end of the long axis. All measurements were recorded on videotape and analyzed off-line 
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by the same observer who was unaware of the clinical details of the participants. The 
interventricular septal wall thickness (IVS) at end diastole and end systole, the posterior wall 
thickness (PWT) at end diastole and end systole and the end diastolic and end systolic internal 
dimensions of the left ventricle were measured only when appropriate visualization of both the 
right and the left septal surfaces occurred. Figure 2.5 shows a representative M-mode image 
employed to assess left ventricular mass and systolic function. 
Left ventricular mass was derived according to an anatomically validated formula 
(Devereux et al 1986) (LVM = 0.8 x [1.04 (LVEDD + IVS +PWT) 3 – (LVEDD) 3] + 0.6g) and 
indexed to height2.7 (LVM index, LVMI). Left ventricular relative wall thickness (RWT) was 
calculated as (LV diastolic posterior wall thickness x2)/LV end diastolic diameter (Ganau et 
al1992). Left ventricular mean wall thickness was determined from the mean of LV septal and 
posterior wall thickness. Left ventricular ejection fraction, and endocardial and midwall fractional 
shortening will be calculated from dimension measurements using standard formulae, where: 
LV ejection fraction (EF) = (LVED volume- LVES volume)       x 100 
 LVED volume 
LV endocardial fractional shortening (FSend) = (LVEDD- LVESD )    x 100 
LVEDD 
LV midwall fractional shortening (FSmid) =  
[([PWTed + SeptalTed]/2 + LVEDD) – ([PWTes + SeptalTes]/2 + LVESD)]     x 100 
  ([PWTed + SeptalTed]/2 + LVEDD) 
where LVED = left ventricular end diastolic, LVES = left ventricular end systolic, LVEDD = LVED 
internal diameter, LVESD= LVES internal diameter, PWTed = end diastolic posterior wall 
thickness, PWTes = end systolic posterior wall thickness, SeptalTed = end diastolic septal wall  
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Figure 2.5. A two-dimensional guided (upper panel) M-mode echocardiographic image (lower 
panel) derived from a Hewlett Packard model 5500 utilised to assess left ventricular dimensions 
and function.EDD, end diastolic diameter, ESD, end systolic diameter, PWTd, posterior wall 
thickness at the end of diastole, PWTs, posterior wall thickness at the end of systole, SeptTd, 
end diastolic septal wall thickness, SeptTs, end systolic septal wall thickness. 
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thickness, and SeptalTes = end systolic septal wall thickness. Left ventricular volumes were 
calculated from left ventricular diameters using the Teichholz formula (Teichholz et al 1976). 
Left ventricular hypertrophy (LVH) was defined as a LVMI >51 g/m2.7 for both women and 
men (Nunez et al 2005). A concentric LV was defined as a RWT>0.45. A concentric LVH was 
defined as the presence of LVH and a RWT>0.45. Eccentric LVH was defined as the presence 
of LVH and a RWT≤0.45. Concentric remodelling was defined as the presence of a RWT>0.45, 
but without LVH. 
Intra-observer variability studies were conducted on 29 subjects on whom repeat 
echocardiographic measurements have been performed within a two week period of the initial 
measurements. The Pearson’s correlation coefficients for LV end diastolic diameter, septal wall 
thickness and posterior wall thickness were 0.76, 0.94 and 0.89 (all p<0.0001) respectively, and 
the variances (mean % difference ± SD) were 0.12±5.95%, -0.77±4.47% and 0.67±5.57% 
respectively. In addition, no significant differences between repeat measurements were evident 
on paired t-test analysis (p=0.99, p=0.42 and p=0.48 respectively). 
 
2.3 Data analysis. 
 
In the animal study, data are represented as either mean±SEM or mean±SD. For 
comparisons of groups in the animal study, an unpaired Student’s t test was performed. For a 
comparison of the thermal response index after versus before LPS injection, a paired Student’s t 
test was performed.    
Database management and statistical analyses for the study conducted on the community 
sample was performed with SAS software, version 9.1 (The SAS Institute Inc., Cary, North 
Carolina, USA). Data from individual subjects were averaged and expressed as mean±SD. The 
Χ2-statistic was used to compare means and proportions. To assess the relationship between 
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indices of adiposity or serum hs-CRP concentrations and indices of left ventricular function, 
multivariate linear regression analyses was performed with age, blood pressure, gender, regular 
alcohol abuse, regular smoking and the presence or absence of diabetes mellitus or abnormal 
blood glucose control in the regression models. Probability values were obtained with further 
adjustments for non-independence of family members (mixed model as outlined in the SAS 
package). As hs-CRP concentrations were not normally distributed they were log transformed to 
achieve a more uniform distribution.   
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Chapter 3 
 
 Results 
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As indicated in chapters 1 and 2, in the present dissertation two separate studies were 
conducted, one in rats and one in a cross-sectional population sample. For ease of reading, the 
results for these two studies will also be described in separate sections. 
   
3.1 Results for the study to assess whether pyrogenic doses of LPS promote 
cardiomyocyte apoptosis in rats. 
 
3.1.1 Diurnal temperatures and thermal responses to lipopolysaccharide 
  
Figure 3.1 shows the mean and SD of core body temperatures as determined in rats 
prior to LPS administration over 3 days. A typical circadian rhythm of core body temperature 
was observed, with night body temperatures being higher than day body temperatures. Core 
body temperature was lowest first thing in the morning and highest in the evening, whilst a 
gradual increase in body temperature was noted through the day. Figure 3.2 shows the thermal 
response index (upper panel) and the temperatures measured over 6 hours (lower panel) in 
response to a single LPS or vehicle injection. Data are compared to that obtained at the same 
time of day over 3 days of temperature measurement in the same rats. Rats receiving LPS 
exhibited a marked thermal response as compared to rats receiving the saline vehicle. In this 
regard, rats developed a fever, as indicated by a temperature increase of greater than 1°C. The 
fever response peaked at 3 hours post LPS administration. Figure 3.3 shows the thermal 
response index after a single (upper panel) and after a second (lower panel) injection of LPS or 
the vehicle injection in rats. The thermal response index after LPS administration was similar on 
the second as compared to the first day. 
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Figure 3.1. Body temperature variations for 13 rats over a period of three days prior to 
lipopolysaccharide (LPS) administration. Hatched bars indicate periods of darkness. Data are 
means and SD. 
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Figure 3.2. Thermal response index (upper panel) and the temperatures measured over 6 
hours (lower panel) in response to lipopolysaccharide (LPS) at 250 µg/kg or the vehicle injection 
in rats. Also shown are data obtained at the same time of day over 3 days of temperature 
measurement in the same rats (circadian rhythm).*p<0.05, vs LPS and saline circadian rhythm. 
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Figure 3.3. Thermal response index after a single (upper panel) and after a second (lower 
panel) injection of lipopolysaccharide (LPS) at 250 µg/kg or the vehicle injection in rats. Data 
shown are obtained over 6 hours at the same time of day.* p<0.05, vs saline and LPS circadian 
rhythm. 
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3.1.2 Echocardiographic data in rats 
 
 Figure 3.4 shows left ventricular endocardial and midwall fractional shortening values, 
heart rates, and end diastolic diameters obtained in rats after having received either LPS or the 
vehicle. No differences in either left ventricular systolic chamber function (endocardial fractional 
shortening), myocardial function (midwall fractional shortening), heart rate, or left ventricular end 
diastolic diameters were noted between rats receiving LPS or the saline vehicle. 
 
3.1.3 Percentage cardiomyocyte apoptosis 
 
Figure 3.5 shows the percentage cardiomyocytes that were TUNEL positive stained in 
the left ventricle of rats 6 hours after receiving a second dose of either LPS or the saline vehicle. 
Lipopolysaccharide administration, despite producing a marked febrile response (see section 
3.1.1) failed to induce a significant increase in TUNEL positive stained cardiomyocytes. 
  
3.2  Results of the study to assess whether inflammation in-part explains the 
relationship between obesity and myocardial dysfunction. 
  
3.2.1 Characteristics of the participants. 
 
Table 3.1 gives the characteristics of the study participants not receiving 
antihypertensive therapy in whom echocardiography was performed as well as the 
characteristics of the participants not receiving antihypertensive therapy in whom did not 
consent to echocardiography, had poor quality echocardiograms, or had insufficient serum for  
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Figure 3.4. Left ventricular function, diameters and heart rate in rats 6 hours after having 
received a second dose of either lipopolysaccharide (LPS) at 250 µg/kg or the saline vehicle. 
FSend, endocardial fractional shortening; FSmid, midwall fractional shortening; EDD, end 
diastolic diameter; HR, heart rate. 
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Figure 3.5. Percentage of rat left ventricular cardiomyocytes showing TUNEL positive staining, 
6 hours after rats have received a second dose of either lipopolysaccharide (LPS) at 250 µg/kg 
or the saline vehicle. 
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Table 3.1. Characteristics of study participants and participants excluded from analysis. 
            Study group  Excluded participants 
____________________________________________________________________ 
Number (% female)          292 (62.0)             248 (60.0) 
Age (years)            39±17*     36±16 
Height (m)          162.5±8.6   161.1±8.9 
Weight (kg)         74.7±18.8   72.4±18.2 
Body mass index (kg/m2)        28.4±7.3   28.0±7.2 
Waist circumference (cm)      87.9±15.3   86.7±15.7 
Mean skin-fold thickness (cm)     2.08±1.13   2.05±1.16 
% overweight/obese       25.0/37.7   22.1/36.4 
% with central obesity           37.0     36.9 
% with hypertension           24.9     21.1 
% with DM or HbA1c>6.1%          17.5     12.1 
Regular smoking (%)          14.0     12.5 
Regular alcohol (%)          24.0*     15.3 
Conventional SBP/DBP (mm Hg)      128±21/83±12                   125±19/83±11 
Conventional PP (mm Hg)      44.5±13.8   42.3±12.2 
LVED diameter (cm)         4.74±0.50        -  
LVED septal thickness (cm)     1.01±0.15        - 
LVED posterior wall thickness (cm)    0.97±0.13        - 
LVED mean wall thickness (cm)    0.99±0.14        - 
LVM (g)        167±47        - 
LVM indexed for BSA (g/m2)     93.6±22.8        - 
LVM indexed for height2.7 (g/m2.7)    45.2±12.6        - 
DM, diabetes mellitus; HbA1C, glycated haemoglobin; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; PP, pulse pressure; LV, left ventricle; LVED, LV end diastolic; LVM, LV 
mass; BSA, body surface area. *p<0.05 vs excluded participants. 
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CRP measurements. More women than men participated. In general the group had a high BMI, 
with ~63% of participants being either overweight (~25%) or obese (~38%) and ~37% having 
central obesity. More women than men were obese with 50% of women and 18% of men being 
obese and 53% of women and 12% of men having central obesity. ~25% of participants were 
hypertensive. ~18% had diabetes mellitus or an impaired blood glucose control (HbA1c>6.1%). 
A relatively low proportion of participants reported smoking or a regular intake of alcoholic 
beverages. ~29% of men and ~20% of women with echocardiographic data had LVH. ~6.5% of 
participants with echocardiographic data had concentric LVH, ~17% eccentric LVH and ~15.4% 
concentric LV remodelling. Except for being slightly younger and consuming less alcohol no 
differences were noted in the characteristics of participants excluded from the analysis because 
of a lack of echocardiographic data or available hs-CRP concentrations (Table 3.1). Mean (±SD) 
CRP concentrations in mg/l was 6.0± 8.8, with the mean CRP concentrations for women being 
7.2±9.4 and for men being 4.1±7.4 (p<0.0001). Fifteen % of participants had elevated CRP 
concentrations. 
 
3.2.2 Factors associated with log C-reactive protein. 
 
On univariate analysis, all adiposity indexes (Figure 3.6), age (r=0.34, p<0.0001), female 
gender (r=0.23, p<0.0001), physical activity (r=0.26, p<0.0001), menopausal status (r=-0.14, 
p<0.05), use of medication in the last two weeks (r=-0.15, p=0.01), and diabetes mellitus or 
inappropriate glucose control (r=0.33, p<0.0001) were all associated with log CRP. In 
multivariate models, both BMI (partial r=0.36, p<0.0001), WC (partial r=0.35, p<0.0001) and 
skin-fold thickness (partial r=0.27, p<0.001) were strong independent predictors of log CRP. 
Similarly, in gender-specific analysis, BMI was the strongest independent predictor of log CRP 
in both men (r=0.28, p<0.005) and women (r=0.39, p<0.0001). 
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Figure 3.6. Relationship between indices of adiposity and C-reactive protein. BMI, body mass 
index; WHR, waist-to-hip ratio. 
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3.2.3 Individual factors correlated with left ventricular systolic function. 
 
On bivariate analysis, waist circumference and skin-fold thickness were inversely 
correlated with left ventricular midwall fractional shortening (Figure 3.7) and BMI (r=-0.14, 
p=0.02) and waist-to-hip ratio (r=-0.12, p<0.05) were marginally and inversely correlated with 
left ventricular midwall fractional shortening. Importantly, log CRP was also inversely correlated 
with left ventricular midwall fractional shortening (Figure 3.7). In addition, age (r=-0.16, p<0.01), 
diabetes mellitus or an HbA1c>6.1% (r=-0.15, p=0.01), systolic BP (r=-0.13, p<0.05), pulse 
pressure (r=-.013, p<0.05), and regular alcohol use (r=-0.12, p<0.05) were inversely associated 
with left ventricular midwall fractional shortening. Neither diastolic blood pressure (r=-0.08, 
p=0.17), regular tobacco intake (r=0.03, p=0.67), gender (r=-0.007, p=0.91) nor left ventricular 
mass index (r=0.02, p=0.76) were correlated with midwall fractional shortening. 
On bivariate analysis neither waist circumference (Figure 3.7), skin-fold thickness 
(Figure 3.7), BMI (r=0.09, p=0.13), waist-to-hip ratio (r=0.03, p=0.56), sex (r=0.006, p=0.92), 
age (r=0.04, p=0.50), systolic blood pressure (r=0.02, p=0.69), diastolic blood pressure (r=0.07, 
p=0.22), pulse pressure (r=-0.03, p=0.63), diabetes mellitus or an HbA1c>6.1% (r=0.03, 
p=0.67),  regular tobacco intake (r=0.09, p=0.13), regular alcohol intake (r=-0.05, p=0.44), or left 
ventricular mass index (r=-0.008, p=0.89) were correlated with left ventricular endocardial 
fractional shortening. Moreover, log CRP was not correlated with left ventricular endocardial 
fractional shortening (Figure 3.8). 
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Figure 3.7. Relationship between indices of adiposity and left ventricular midwall (FSmid) and 
endocardial (FSend) fractional shortening. 
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Figure 3.8. Relationship between log C-reactive protein (CRP) and left ventricular midwall 
(FSmid) or endocardial (FSend) fractional shortening. 
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3.2.4 Independent associations with left ventricular systolic function. 
 
Table 3.2 shows the factors independently associated with left ventricular midwall 
fractional shortening. On multivariate regression analysis with waist circumference included as 
an index of adiposity. In a multivariate model without log CRP in the model, only waist 
circumference was independently and inversely associated with left ventricular midwall 
fractional shortening. In a multivariate model with log CRP but without waist circumference 
included in the model, log CRP was not independently associated with left ventricular midwall 
fractional shortening. 
 
3.2.5 Independent associations with left ventricular systolic function with both waist 
circumference and C-reactive protein in the same model. 
 
 With both waist circumference and log hs-CRP in the same regression model, waist 
circumference still showed an independent association with fractional midwall shortening 
(standardized β-coefficient=-0.18±0.08, p=0.021). The slope of the relationship (standardized β-
coefficient) between waist circumference was similar before (see Table 3.2) and after the 
inclusion of log hs-CRP in the regression model.   
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Table 3.2. Independent associations with left ventricular midwall fractional shortening in 
multivariate regression models in the study group (n=292). 
 
                  Standardized        p value for 
Left ventricular midwall            β-coefficient±SEM          relationship 
fractional shortening vs        
     With waist circumference but not log CRP in the model 
Age            -0.05±0.08   0.52      
Waist circumference             -0.19±0.07   <0.01   
Systolic blood pressure         -0.07±0.08   0.35 
Female sex           0.05±0.06   0.28   
DM or HbA1c>6.1%          0.07±0.06   0.03 
Left ventricular mass index          0.16±0.07   0.02   
Regular alcohol           0.13±0.06   0.02 
     With log CRP but not waist circumference in the model 
Age            -0.11±0.08   0.16      
Log CRP              -0.08±0.07   0.21   
Systolic blood pressure         -0.09±0.08   0.26 
Female sex           0.03±0.06   0.59   
DM or HbA1c>6.1%          0.08±0.06   0.23 
Left ventricular mass index          0.14±0.07            <0.05   
Regular alcohol           0.13±0.06            <0.05 
______________________________________________________________________ 
Probability values were further adjusted for non-independence of family members. Significant 
probability values indicating inverse associations with left ventricular midwall fractional 
shortening are indicated in bold.  
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Chapter 4 
 
Discussion 
70 
 
In the present chapter, consistent with the sequence followed in chapters 2 and 3 of the 
present dissertation, I will first discuss how the studies performed in my dissertation have 
furthered our understanding of the potential role of low-grade infections in promoting adverse 
cardiac changes. Second, I will discuss how the studies performed in my dissertation have 
enhanced our understanding of the role of obesity-induced inflammatory changes in promoting 
cardiac dysfunction. 
 
4.1. Lipopolysaccharide effects on cardiomyocyte apoptosis 
 
As reviewed in chapter 1 of the present dissertation, a number of studies indicate that 
LPS mediates cardiomyocyte apoptosis (Li et al 2002, Suzuki et al 2003, Suzuki et al 2007, 
Comstock et al 1998, McDonald et al 2000). The potential mechanism of the LPS-induced 
cardiomyocyte apoptotic effect is through Toll-like receptor activation, which stimulates 
cardiomyocyte angiotensinogen expression, and hence through angiotensin II, promotes 
calcineurin-induced cardiomyocyte programmed cell death (Suzuki et al 2007). In addition, the 
LPS-induced cardiomyocyte apoptotic effect may also be mediated through TNF-α effects 
(Cowan et al 2001, Peng et al 2005). These findings of an effect of LPS on cardiomyocyte 
apoptosis (Li et al 2002, Suzuki et al 2003, Suzuki et al 2007, Comstock et al 1998, McDonald 
et al 2000) are of major clinical importance in sepsis and septic shock which are frequently 
associated with a profound decrease in cardiac function (Calvin et al 1981, Parker et al 1984, 
Jafri et al 1990, Munt et al 1998, Poelaert et al 1997). Indeed, inhibition of caspase, the key 
enzyme involved in promoting apoptotic pathways, prevents cardiac dysfunction and 
cardiomyocyte apoptosis in an animal model of sepsis (Neviere et al 2001). However, can one 
extrapolate these data to a potential clinically relevant effect in chronic infections or infections 
which are not associated with the haemodynamic changes that accompany sepsis? 
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It is possible that with repeated inflammatory responses, modest degrees of 
cardiomyocyte apoptosis, with no immediate effect on heart function, could ultimately translate 
into a significant degree of myocardial damage, thus heralding the onset of heart failure after a 
prolonged time-period. This hypothesis is based on the findings that increased circulating LPS 
concentrations do indeed occur in chronic sub-clinical infections associated for example with a 
poor dental hygiene (Moutsopoulos and Madianos 2006, Geerts et al 2002). The authors of 
some of the studies showing that cardiomyocyte apoptosis occurs in response to LPS (Li et al 
2002, Suzuki et al 2003, 2007) have suggested that the cardiomyocyte apoptotic effect occurs 
at sufficiently low enough concentrations of LPS as to be comparable with the LPS 
concentrations that occur in chronic infections. However, the LPS dose employed in these 
studies (I mg/kg) (Suzuki et al 2003, Suzuki et al 2007, Li et al 2002) has recently been reported 
to produce a marked decrease in blood pressure and cerebral vasodilation, an increased 
circulating lactate concentration, and a metabolic acidosis with a compensatory decrease in 
PaCO2 (respiratory drive) (Rosengarten et al 2008). 
It would thus appear that the dose of LPS administered to induce cardiomyocyte 
apoptosis is more likely to induce all of the changes that one would normally consider to be 
congruent with septic shock. Thus, an outstanding question is whether low-grade infections, 
without the changes associated with septic shock, are indeed able to produce cardiomyocyte 
apoptosis. 
 
4.1.1 Lipopolysaccharide-induced effects on cardiomyocyte apoptosis: Outcomes of 
the present study and comparison with previous studies 
 
In the present study although LPS given at significantly lower doses (250 µg/kg) than the 
doses given in those studies that have shown an LPS-induced cardiomyocyte apoptotic effect (I 
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mg/kg) (Suzuki et al 2003, Suzuki et al 2007, Li et al 2002) induced a marked febrile response, 
cardiomyocyte apoptosis was not observed. Although the apparent inconsistencies in LPS-
induced cardiomyocyte apoptosis between the results in the present dissertation and those 
previously reported on (Comstock et al 1998, Li et al 2002, Suzuki et al, 2003, 2007, McDonald 
et al 2000, Chagnon et al 2005, Niu et al 2008) are likely to be explained by differences in the 
LPS doses employed, other explanations need to be considered. 
Importantly, in previous studies, cardiomyocyte apoptosis as assessed from caspase 3 
activity was observed within 4 hours of LPS administration and did not dissipate over 24 hours 
(Suzuki et al 2007). Consequently, it is unlikely that differences in the time taken to assess 
apoptosis (6 hours after a second dose of LPS in the present study) contributed to the 
differences in the outcomes of the present and previous (Suzuki et al 2003, Suzuki et al 2007, Li 
et al 2002) studies. Importantly, the time period of 6 hours post LPS administration was selected 
to assess cardiomyocyte apoptosis in the present study to ensure that hearts were obtained in a 
period where there was still evidence of a febrile response. Indeed, the time of termination of 
rats coincided with a body temperature that was still higher than rats receiving the vehicle 
control and higher than the body temperature of the same rats measured at the same time of 
day on a preceding day in the absence of LPS. Moreover, cardiomyocyte apoptosis was 
assessed not only 6 hours after a dose of LPS administered on the same day, but also 24-hours 
after a dose of LPS administered on the preceding day. Consequently in the present study I was 
able to assess the impact of LPS on cardiomyocyte apoptosis over a 6-24 hour period, which 
encompasses the time periods within which LPS-induced cardiomyocyte apoptosis would be 
expected to occur (Suzuki et al 2007). A study with further time periods included would 
obviously strengthen the conclusions of the present study. However, based on previous 
evidence of the optimal time period of 4-24 hours (Suzuki et al 2007), this is unlikely to occur. 
Moreover, I could have considered assessing the effect of daily doses of LPS for prolonged 
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periods thus evaluating whether a cumulative effect on the heart could have occurred. However, 
consideration would have to be given to repeated injections of LPS and the possibility of LPS 
tolerance developing (Roth et al 1994). Indeed, in the present study, although there was no 
statistically significant tolerance, the thermal response index did tend to decrease on day 2. 
Further injections of LPS are therefore likely to have resulted in significant tolerance.  
Although not measured in the present study, but as would be expected, a febrile 
response induced by LPS administration, such as noted in the present study, is associated with 
increased circulating concentrations of inflammatory mediators, such as TNF-α (Givalois et al 
1994, Roth et al 1991). In this regard, although TNF-α at high concentrations has been shown 
to reduce cardiomyocyte function and promote myocardial damage (reviewed by Mann 2002, 
Kelly and Smith 1997) TNF-α at sufficiently low concentrations has cardio-protective effects on 
the heart (Deuchar et al 2007, Lecour et al 2002, Tanno et al 2003, Kurrelmeyer et al 2000). It is 
therefore possible that in response to LPS, increased circulating TNF-α concentrations, or an 
increased myocardial TNF-α expression in the present study may have only been sufficient to 
produce protective, rather than destructive effects on the heart. In contrast, at higher LPS doses 
such as those employed by previous authors (Suzuki et al 2003, Suzuki et al 2007, Li et al 
2002), the extent to which TNF-α concentrations, or an increased myocardial TNF-α expression 
may have increased could have been sufficient to promote myocardial damage. Neither in our 
study, nor in previous studies have circulating TNF-α concentrations, or an increased 
myocardial TNF-α expression been measured in response to LPS and correlated with 
cardiomyocyte apoptosis or the lack thereof. Further studies are required to evaluate these 
possibilities. 
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4.1.2 Lipopolysaccharide-induced effects on cardiac function: Outcomes of the present 
study and comparison with previous studies. 
 
As reviewed in chapter 1, LPS depresses myocardial and cardiomyocyte function 
(Suffredini et al 1989, Brady et al 1992, Hung and Lew 1993a, 1993b, Tao and McKenna 1994, 
Nishikawa et al 1995, Nishikawa and Lew 1996, Lew et al 1996, 1997a, Stein et al 1996, 
Yasuda and Lew 1997a, 1997b, 1999, Tavener et al 2004). In contrast, in the present study I 
failed to show an effect of LPS on cardiac systolic function and this outcome is consistent with a 
lack of adverse effects of LPS on noradrenaline-mediated increases in contractile function in 
isolated cardiomyocytes previously reported on in one study (Muller-Werdan et al 1998). The 
explanation for the lack of effect of LPS on cardiac systolic function in the present study is most 
likely because of the low dose of LPS employed in the present as compared to previous studies 
(Suffredini et al 1989, Brady et al 1992, Hung and Lew 1993a, 1993b, Tao and McKenna 1994, 
Nishikawa et al 1995, Nishikawa and Lew 1996, Lew et al 1996, 1997a, Stein et al 1996, 
Yasuda and Lew 1997a, 1997b, 1999, Tavener et al 2004). In the present study the purpose of 
LPS administration was to mimic the inflammatory effects of a low-grade systemic infection, 
rather than septic shock. In previous studies (Suffredini et al 1989, Brady et al 1992, Hung and 
Lew 1993a, 1993b, Tao and McKenna 1994, Nishikawa et al 1995, Nishikawa and Lew 1996, 
Lew et al 1996, 1997a, Stein et al 1996, Yasuda and Lew 1997a, 1997b, 1999, Tavener et al 
2004) however, the purpose of these studies was to attempt to mimic septic shock. 
In the present study the evidence to support a view that the dose of LPS does not induce 
septic shock was the presence of heart rates and left ventricular end diastolic diameters in rats 
receiving LPS that were similar to the control rat values. In septic shock, left ventricular end 
diastolic diameter is likely to decrease as a consequence of a reduced venous return (through 
the effects of peripheral pooling). Furthermore, if blood pressures had decreased acutely as a 
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consequence of a septic shock state, a baroreceptor response is likely to have resulted in an 
increased heart rate. As this was not apparent, it is unlikely that septic shock occurred in the 
present study.  
 
4.1.3 Lipopolysaccharide-induced effects on the heart: Study strengths and limitations 
 
The strengths of the present study are as follows. First, I used surgically implanted 
radiotelemeters to establish the physiological response to LPS and to ensure that 
cardiomyocyte apoptosis was assessed as guided by changes in core body temperature as well 
as time after injection. Second, to ensure that LPS did not produce changes consistent with 
septic shock, echocardiography was performed to assess filling diameters, heart rates and 
systolic cardiac function. 
The weaknesses of the present study are as follows: The only method that I employed to 
assess cardiomyocyte apoptosis was a TUNEL technique. Importantly, in our groups hands this 
has previously been successful in showing hypertensive associated (Veliotes et al 2005) and 
adrenergic-induced (Osadchii et al 2007) cardiomyocyte apoptosis. However, TUNEL may 
overestimate the number of apoptotic nuclei, as it labels both DNA fragmentation and cells 
undergoing DNA repair. This is obviously not a concern in the present study as this would have 
biased against a result of a lack of effect of LPS on cardiomyocyte apoptosis. Alternative 
techniques such as the assessment of myocardial caspase-3 activity or other methods including 
DNA laddering could have been employed to support the present outcomes. 
A second limitation of the present study is that ideally, the present study would have 
benefitted from a group of rats receiving a high dose of LPS, a dose previously shown to induce 
cardiomyocyte apoptosis (I mg/kg) (Suzuki et al 2003, Suzuki et al 2007, Li et al 2002) to act as 
a positive control group. However, this was not possible for ethical reasons due to the possibility 
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that this dose is capable of producing haemodynamic and other changes consistent with septic 
shock (Rosengarten et al 2008). Indeed, in discussion with the chairperson of the Animal Ethics 
Screening Committee, it is unlikely that this committee would ever approve an application of a 
model of septic shock in unanaesthetised animals. 
Additional limitations of the present study include the following: I assessed the effect of a 
relatively short-term period of LPS exposure on cardiomyocyte apoptosis. In this regard I cannot 
exclude the possibility that further exposure to LPS in long-term studies may ultimately result in 
increases in cardiomyocyte apoptosis. Moreover, although I assessed the impact of LPS on 
cardiomyocyte apoptosis, I failed to evaluate the effect on cardiomyocyte autophagy. Further 
work is therefore required to address these questions.  
 
4.1.4 Lipopolysaccharide-induced effects on the heart: Clinical implications. 
 
 The outcomes of the present study support the view that LPS at concentrations that 
induce a low-grade systemic infection do not result in increases in cardiomyocyte apoptosis. 
Hence, the present study suggests that LPS-induced cardiomyocyte apoptosis demonstrated in 
previous studies (Li et al 2002, Suzuki et al 2003, Suzuki et al 2007, Comstock et al 1998, 
McDonald et al 2000) is probably important with respect to the impact of LPS in sepsis but not in 
low-grade systemic infections. Further long-term studies are nevertheless still required to 
substantiate these outcomes. Moreover, the outcomes of the present study need to be 
confirmed using alternative assessments of cardiomyocyte apoptosis or assessments of 
alternative cell death mechanisms including cardiomyocyte autophagy. 
 
4.2 Outstanding question regarding the role of inflammation in obesity-induced 
cardiac dysfunction 
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As described in chapter 1 of the present dissertation, few studies have assessed 
whether circulating inflammatory markers may explain the association that exists between 
obesity and heart failure or cardiac dysfunction. In support of a role for obesity-derived 
inflammatory substances as mediators of heart failure, after adjustments for either interleukin-6 
or C-reactive protein in the regression analysis, the independent relationship between obesity 
and heart failure failed to achieve statistical significance (Bahrami et al 2008). However, in that 
study (Bahrami et al 2008) the increased risk for heart failure in obese patients decreased from 
an 83% (hazards ratio=1.83) to a 50-58% (hazards ratio=1.50-1.58) risk after adjustments for 
inflammatory markers. Thus, a potential residual risk for heart failure remained even after 
adjustments for pro-inflammatory markers (Bahrami et al 2008). In support of this notion, in 
another study (Spies et al 2009), the independent relationship between waist-to-hip ratio and 
the subsequent development of heart failure in patients with established coronary artery disease 
was only partially modified with adjustments for CRP, TNF-α, or interleukin-6. In that study 
(Spies et al 2009), the independent relationship between an excess adiposity and the 
development of heart failure remained even after adjustments for these inflammatory markers. 
Thus, there is still considerable controversy as to the role of adipose tissue-derived pro-
inflammatory substances in the development of obesity-induced heart failure. Before describing 
the main outcomes of the present study assessing whether obesity-induced cardiac systolic 
dysfunction can be accounted for by serum CRP concentrations, it is important to first place the 
study group in context. In this regard, the first important question is whether in the present study 
cohort there was evidence that obesity contributes toward circulating concentrations of serum 
CRP? 
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4.2.1 Relationship between obesity and CRP: Outcomes of the present study and 
comparison with previous studies. 
 
In the present study I noted relatively strong relationships between serum CRP 
concentrations and indices of an excess adiposity, which persisted even when correcting for 
conventional risk factors in multivariate regression models. These findings are in agreement 
with previous studies demonstrating independent relationships between indices of adiposity and 
circulating concentrations of inflammatory markers, including CRP (Bahrami et al 2008, Berg 
and Scherer 2005, Despres et al 2006, Ridker et al 2003 and Sattar et al 2007, Yudkin et al 
1999, Cartier et al 2009a, Piche et al 2005). Although associations do not indicate cause and 
effect, other studies have provided sufficient evidence to suggest that these relations are indeed 
cause and effect, as weight loss with liposuction (Giugliano et al 2004), gastric bypass (Kopp et 
al 2003) and diet (Heilbronn et al 2001) have all been shown to decrease circulating 
concentrations of inflammatory markers. 
In keeping with previous studies demonstrating correlation coefficients of.0.21-0.61 for 
relationships between adiposity indices and circulating CRP concentrations (Yudkin et al 1999, 
Cartier et al 2009a, 2009b, Lemieux et al 2001, Piche et al 2005), in the present study I could 
similarly show correlation coefficients for the relationships between indices of an excess 
adiposity and circulating CRP concentrations ranging from 0.21-0.51, with BMI and waist 
circumference showing the strongest correlations. Although a greater number of women 
participated in the present study than men, and consistent with previous studies (Khera et al 
2009) female gender was independently associated with circulating CRP concentrations, the 
relationship between indices of adiposity and serum CRP was similar in both gender groups.   
Importantly, in the present study BMI was equally as strongly associated with serum 
CRP concentrations as was waist circumference. This is in contrast to the stronger relationships 
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noted between indices of central obesity and circulating CRP concentrations as compared to 
alternative adiposity indices and circulating CRP concentrations previously suggested (Piche et 
al 2005, Yudkin et al 1999, Lemieux et al 2001, Cartier et al 2009a, 2009b). However, in 
previous studies, despite the claim that central adiposity is the primary determinant of CRP 
(Yudkin et al 1999, Cartier et al 2009a, 2009b, Hak et al 1999), only one study (Hak et al 1999) 
showed that the relationship between central adiposity and inflammation was independent of the 
effect of BMI. 
 It is possible that in the present study the inability to show a stronger relationship 
between indices of central adiposity as compared to alternative indices of adiposity and 
circulating CRP concentrations may be explained by the strength of the relationship between 
BMI and waist circumference in the population sampled (Majane et al 2008). It may also be 
argued that because more women than men participated in the present study, and that 
circulating CRP concentrations are related to subcutaneous rather than visceral fat in women 
and visceral rather than subcutaneous fat in men (Cartier et al 2009b), that this may explain the 
similarity in the strength of the associations between indices of central or general adiposity and 
circulating CRP concentrations. However, alternative studies indicate that there is a stronger 
association between indices of central obesity and circulating CRP concentrations in both 
genders (Khera et al 2009). Moreover, in the present study, gender-specific analysis revealed 
that BMI was the strongest independent predictor of circulating CRP concentrations in both men 
and women. Further studies conducted in a much larger cohort of participants are required to 
explain the equivalence of the strength of the relationship between BMI and serum CRP 
concentrations as compared to waist circumference and serum CRP concentrations in the 
present community.  
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4.2.2 Relationship between obesity and cardiac systolic function: Outcomes of the 
present study and comparison with previous studies. 
 
 In the present study I noted an inverse relationship between two indices of adiposity 
(waist circumference and skin-fold thickness) and an index of myocardial systolic function (left 
ventricular midwall fractional shortening), and the relationship between waist circumference and 
left ventricular midwall fractional shortening persisted with adjustments for potential 
confounders. However, I was unable to show an unadjusted or multivariate adjusted relationship 
between indices of adiposity and left ventricular chamber systolic function. 
The independent relationship between an excess adiposity and left ventricular 
myocardial systolic function noted in the present study is consistent with decreases in tissue 
Doppler indices of systolic myocardial function noted to occur in overweight and obese people 
without conventional cardiovascular risk factors previously reported on (Peterson et al 2004, 
Wong et al 2004). Whether the relationships between an excess adiposity and myocardial 
systolic function are cause-effect relationships is nevertheless unclear. Indeed, even with the 
use of load-independent tissue Doppler measures of myocardial as opposed to chamber 
function, or with chamber function assessments, weight loss produced by either lifestyle 
modification or gastric bypass does not influence left ventricular systolic function (Willens et al 
2005, Rider et al 2009, Wong et al 2006, Skilton et al 2007). 
In contrast to the present study one previous study has failed to demonstrate a 
relationship between body size and left ventricular midwall fractional shortening (De Simone et 
al 1996). Nevertheless, in contrast to the present study where the participants studied 
comprised largely of normotensives (~75% of the sample) not receiving antihypertensive 
therapy, in the study by De Simone et al (1996), the relationship between obesity and left 
ventricular midwall fractional shortening was studied in hypertensives only. As hypertension is a 
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well-recognized cause of myocardial systolic dysfunction, this may have obscured the impact of 
obesity on myocardial function. Differences in the prevalence of obesity could also account for 
differences in the relationship between adiposity indices and left ventricular midwall fractional 
shortening in the present study as compared to the study by De Simone et al (1996) where no 
independent relationship was noted. Indeed, the prevalence of obesity in the present study 
(~37%) was greater than that reported on by De Simone et al (1996)(26.1%). In addition, in the 
study by De Simone et al (1996), the relationship between indices of an excess adiposity and 
left ventricular midwall fractional shortening was unlikely to have been assessed in a cohort in 
which the prevalence of concentric cardiac remodelling produced by an excess adiposity was as 
high as that described in the present study. Indeed, in the present study 25% of the total sample 
had either concentric left ventricular hypertrophy or remodelling and we have previously 
demonstrated that a substantial proportion on this change is accounted for by obesity 
(Woodiwiss et al 2008). As concentric left ventricular remodelling is thought to be a 
compensatory change that maintains chamber function in the presence of decreases in 
myocardial systolic function as indexed by left ventricular midwall fractional shortening (Norton 
et al 2002), the present study sample is ideally suited to assess whether obesity is associated 
with left ventricular midwall fractional shortening.  
The lack of relationship between indices of excess adiposity and either unadjusted or 
multivariate adjusted values for left ventricular chamber systolic dysfunction (endocardial 
fractional shortening) is not surprising as the independent relationship between an excess 
adiposity and systolic chamber function is controversial, with some studies showing a 
relationship between an excess adiposity and systolic chamber function (Ammar et al 2008, 
Chinali et al 2006, Peterson et al 2004, Wong et al 2004, Scaglione et al 1992, Karason et al 
1998, Alpert et al 1995, Alpert et al 1993), whilst others have failed to do so (Pascual et al 2003, 
Devitiis et al 1981, Zarich et al 1991, Stoddard et al 1992, De Simone et al 1996, Mureddu et al 
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1996, Iacobellis et al 2002). A lack of relationship between indices of an excess adiposity and 
chamber systolic function despite the relationship between indices of an excess adiposity and 
myocardial systolic function is also not surprising considering the high prevalence of concentric 
left ventricular remodelling reported on in the present study, a change attributed to a large 
extent to obesity (Woodiwiss et al 2008). In this regard, as previously indicated, concentric 
remodelling may indeed be a compensatory response to myocardial dysfunction. 
 
4.2.3 Relationship between CRP and cardiac systolic function: Outcomes of the present 
study and comparison with previous studies. 
 
In the present study, an inverse univariate correlation, albeit weak, was noted between 
CRP concentrations and left ventricular midwall fractional shortening, a relationship which 
nevertheless did not persist with adjustments for potential confounders. In addition, the inverse 
relationship between adiposity indices and left ventricular myocardial function remained when 
waist circumference was included in the same regression model with log CRP, whilst log CRP 
was not independently associated with left ventricular systolic myocardial function in this same 
model. These data therefore suggest that inflammatory changes as indexed by log CRP, are 
unlikely to account for the impact of an excess adiposity on left ventricular systolic myocardial 
function. 
The lack of independent relationship between CRP concentrations and left ventricular 
midwall fractional shortening in the present study is in apparent contrast to the evidence to 
suggest that inflammatory markers, including CRP, independently predict the development of 
heart failure (Bahrami et al 2008, Vasan et al 2003, Cesari et al 2003, Ingelsson et al 2005b). 
However, in the present study I assessed left ventricular systolic myocardial function rather than 
heart failure. In this regard, chronic inflammation in the group studied may not have been 
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present for sufficiently long to have produced early changes in myocardial function. In addition, 
this observation may be attributed to the impact of co-linearity in the regression models, an 
effect produced by the close relationship between inflammation and obesity or other factors. 
Only prospective follow-up of participants will provide the necessary evidence to evaluate 
whether in the community studied, CRP concentrations independently predict a reduced 
myocardial systolic function or the development of heart failure. 
The lack of ability of adjustments for CRP concentrations to nullify the inverse 
relationship between adiposity indices and left ventricular myocardial function is in apparent 
contrast to data demonstrating a potential role for obesity-derived inflammation as a mediator of 
heart failure. Indeed, previous studies have demonstrated that after adjustments for either 
interleukin-6 or CRP in the regression analysis, the independent relationship between obesity 
and heart failure failed to achieve statistical significance (Bahrami et al 2008). Moreover, Spies 
et al (2009), have demonstrated that the independent relationship between waist-to-hip ratio 
and the subsequent development of heart failure in patients with established coronary artery 
disease was partially modified with adjustments for CRP, TNF-α, and interleukin-6. However, 
the present data are also in-part in support of that study (Spies et al 2009), as these authors 
(Spies et al 2009), demonstrated that a residual independent relationship between an excess 
adiposity and the development of heart failure remained even after adjustments for these 
inflammatory markers. It is also possible that the ability of adjustments of circulating markers of 
inflammatory changes in the regression analysis to reduce the independent relationship 
between obesity and heart failure (Bahrami et al 2008, Spies et al 2009) could be attributed to 
effects of inflammatory changes on diastolic rather than systolic myocardial function, a 
possibility not explored in the present dissertation. 
 
 
84 
 
4.2.4 Inflammation and obesity-induced cardiac dysfunction: Strengths and limitations. 
 
The outcomes of the present study need to be interpreted in the context of the study 
strengths and limitations. The strengths of the present study include the random selection 
techniques of the study sample, and the fact that the question was assessed in a community 
well recognized as having a high prevalence of obesity and where indices of obesity were 
strongly related to circulating CRP concentrations. 
The weaknesses of the present study include the following: First, the sample size 
prevented me, in sensitivity analysis, from assessing relationships between obesity or 
circulating CRP concentrations and myocardial systolic function in subgroups of the study. 
Important subgroups could have been sex-specific groups as gender was associated with log 
CRP. A second limitation of the study was the cross-sectional design. Cross-sectional studies 
prevent the ability to draw conclusions regarding cause and effect. Only longitudinal studies 
assessing the ability of CRP to predict the development of systolic dysfunction or intervention 
studies specifically targeting inflammation in obese individuals will allow for cause-effect 
relationships to be established. Third, myocardial tissue doppler measurements of myocardial 
systolic function were not available in the present study and these measurements could be 
more sensitive than calculations of midwall fractional shortening for detecting myocardial 
systolic dysfunction. Fourth, the study is limited by the lack of measurements of circulating 
concentrations of alternative pro-inflammatory and anti-inflammatory adipokine measurements. 
However, no study has yet demonstrated that these measurements offer a greater sensitivity to 
detect adverse effects on the heart than circulating high or CRP concentrations. 
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4.2.5 Inflammation and obesity-induced cardiac dysfunction: Clinical implications. 
 
 The outcomes of the present study suggest that obesity mediates deleterious effects on 
myocardial systolic function through actions that are independent of inflammatory changes. If 
these data are replicated in longitudinal or intervention studies targeting obesity or obesity 
induced inflammatory changes, these data may suggest that targeting obesity-induced 
inflammation may not be an important therapeutic intervention in preventing heart failure 
associated with systolic myocardial dysfunction. Further large community or population-based 
studies and intervention studies are therefore required to evaluate this hypothesis. 
 
4.3 Overall conclusions 
 
 In conclusion, the present studies indicate the following: First, in contrast to the 
cardiomyocyte apoptosis associated with high doses of LPS, the inflammatory response 
produced by doses of LPS associated with a marked pyretic response, but not with sepsis, do 
not result in cardiomyocyte apoptosis as assessed using a TUNEL technique. Second, 
circulating concentrations of the inflammatory marker, CRP, do not account for obesity-induced 
decreases in systolic myocardial function. Although these studies require further work to 
substantiate these outcomes, these outcomes lend insights into the potential role of chronic 
inflammation produced either by infections or obesity on the heart. In this regard, the data 
obtained in the present dissertation suggest that low grade inflammation associated with 
infections or with obesity are unlikely to contribute toward the development of myocardial 
damage or myocardial systolic dysfunction.      
 
86 
 
References 
 
Abbate A, Biondi-Zoccai GGL, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, 
Silvestri F, Biasucci LM, Baldi A. Increased myocardial apoptosis in patients with 
unfavorable left ventricular remodeling and early symptomatic post-infarction heart 
failure. J Am Coll Cardiol 2003;41:753-760. 
Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey CV, Hashimi MW, Mukerji 
V. Relation of duration of morbid obesity to left ventricular mass, systolic function, and 
diastolic filling, and effect of weight loss. Am J Cardiol 1995;76:1194-1197. 
Alpert MA, Terry BE, Lambert CR, Kelly DL, Panayiotou H, Mukerji V, Massey CV, Cohen MV. 
Factors influencing left ventricular systolic function in non hypertensive morbidly obese 
patients and effect or weight loss. Am J Cardiol 1993;15:733-737. 
Ammar KA, Redfield MM, Mahoney DW, Johnson M, Jacobsen SJ, Rodeheffer RJ. Central 
obesity: association with left ventricular dysfunction and mortality in the community. Am 
Heart J 2008;156:975-981. 
Anderson JC, Konz, EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-
analysis of US studies. Am J Clin Nutr 2001;74:579–584. 
Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results 
of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-
130. 
Agarwala S, Kalil RE. Axotomy-induced neuronal death and reactive astrogliosis in the lateral 
geniculate nucleus following a lesion of the visual cortex in the rat. J Comp Neurol 
1998;392:252-263. 
Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik 
T, Simonsen S, Frøland SS, Gullestad L. Cytokine network in congestive heart failure 
87 
 
secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-
382. 
Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima 
JA. Novel metabolic risk factors for incident heart failure and their relationship with 
obesity: the MESA (Multi-Ethnic Study of Athersosclerosis) study. J Am Coll Cardiol 
2008;51:1775-1783. 
Barouch LA, Gao D, Miller KL, Xu W, Phan AC, Kittleson MM, Minhas KM, Berkowitz DE, Wei 
C, Hare JM. Cardiac myocyte apoptosis is associated with increased DNA damage and 
decreased survival in murine models of obesity. Circ Res 2006;98:119-124. 
Bennett CM, Guo M, Dharmage SC. HbA1c as a screening tool for the detection of type 2 
diabetes: a systematic review. Diabet Med 2007;24:333-343. 
Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 
2005;96:939-949. 
Brady AJP, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac 
myocytes reduces their contractility in endotoxaemia. Am J Physiol 1992;263:H1963-
H1966. 
Brooksbanka R, Woodiwiss AJ, Sliwa K, Badenhorst D, Defterios D, Wadee AA, Essop MR, 
Sareli P, Norton GR. Endotoxin-independent white cell cytokine production in 
heamodynamically stable patients with idiopathic dilated cardiomyopathy. Cardiovasc J 
South Afr 2005;16:260-265. 
Brooksbankb R, Woodiwiss AJ, Sliwa K, Badenhorst D, Defterios D, Essop MR, Sareli P, Norton 
GR. Sustained white cell cytokine activation in idiopathic dilated cardiomyopathy despite 
haemodynamic improvement with medical therapy. Cardiovasc J South Afr 2005;16:200-
204. 
88 
 
Cabanac A, Briese E. Handling elevates the colonic temperature of mice. Physiol Behav 
1992;51:95-98. 
Calvin JE, Driedger AA, Sibbald WJ. An assessment of myocardial function in human sepsis 
utilizing ECG gated cardiac scintigraphy. Chest 1981;80:579-586. 
Carabello BA, Gittens L. Cardiac mechanisms and function in obese normotensive persons with 
normal coronary arteries. Am J Cardiol 1987;15:469-473. 
Cartiera A, Cote M, Lemieux I, Perusse L, Tremblay A, Bouchard C, Despres JP. Age-related 
differences in inflammatory markers in men: contribution of visceral adiposity. 
Metabolism 2009;58:1452-1458. 
Cartierb A, Cote M, Lemieux I, Perusse L, Tremblay A, Bouchard C, Despres JP. Sex 
differences in inflammatory markers: what is the contribution of visceral adiposity? Am J 
Clin Nutr 2009;89:1307-1314. 
Carroll JF, Jones AE, Hester RL, Reihart GA, Cockrell K, Mizelle HE. Reduced cardiac 
contractile responsiveness to isoproterenol in obese rabbits. Hypertension 
1997;30:1376-1381. 
Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin 
SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of 
cardiovascular events: Results from the Health ABC Study. Circulation 2003;108:2317-
2322. 
Chagnon F, Metz CN, Bucala R, Lesur O. Endotoxin-induced myocardial dysfunction: effects of 
macrophage migration inhibitory factor neutralization. Circ Res 2005;96:1095-1102. 
Chakko S, Mayor M, Allison MD, Kessler KM, Materson BJ, Myerburg RJ. Abnormal left 
ventricular filling in eccentric left ventricular hypertrophy of obesity. Am J Cardiol 1991;68:95-98. 
89 
 
Chao W, Shen Y, Zhu X, Zhao H, Novikov M, Schmidt U, Rosenzweig A. Lipopolysaccharide 
improves cardiomyocyte survival and function after serum deprivation. J Biol Chem 
2005;280: 1997-2005. 
Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart 
failure in the elderly: a prospective community based study. Am J Med 1999;106:605-
612. 
Cheng YC, Chen LM, Chang MH, Chen WK, Tsai FJ, Tsai CH, Lai TY, Kuo WW, Huang CY, Liu 
CJ. Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in 
H9c2 cardiomyoblast cells. Mol Cell Biochem 2009;325:15-23. 
Chinali M, DeSimone G, Roman MJ, Lee ET, Best LG, Howard BV, Devereux RB. Impact of 
obesity on cardiac geometry and function in a population of adolescents: the Strong 
Heart Study. J Am Coll Cardiol 2006;47:2267-2273. 
Chung ES, Perlini S, Aurigemma GP, Fenton RA, Dobson JG, Meyer TE. Effects of chronic 
adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber 
function in pressure overload hypertrophy in the rat. J Hypertens 1998;16:1813-1822. 
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, 
placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour 
necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the 
anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 
2003;107:3133-3140. 
Cinquegrana G, D'Aniello L, Landi M, Spinelli L, Grande G, De Prisco F, Petretta M. Effects of 
different degrees of sympathetic antagonism on cytokine network in patients with 
ischemic dilated cardiomyopathy. J Card Fail 2005;11:213-219. 
Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, Monk DN, Shenkin A, Hill GL. 
Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic 
90 
 
responses in patients with severe sepsis--a randomized, clinical trial. Crit Care Med 
1998;26:1650-1659. 
 Comstock KL, Krown KA, Page MT, Martin DM Ho P, Pedraza M, Castro EN, Nakajima N, 
Glembotski CC, Quintana PJE, Ra S. LPS-Induced TNF−α release from and apoptosis 
in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol 
Cell Biol 1998;30:2761-2775. 
Cowan DB, Noria S, Stamm C, Garcia LM, Poutias DN, del Nido PJ, McGowan FX. 
Lipopolysaccharide internalization activates endotoxin-dependent signal transduction in 
cardiomyocytes. Circ Res 2001;88:491-498. 
Cowie MR, Wood DA, Coats AJS, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC. 
Survival of patients with a new diagnosis of heart failure:  a population based study. 
Heart 2000;83:505-510. 
De Simone G, Deveroux RB, Mureddu GF, Roman MJ, Ganau A, Saba PS, Alderman MH, 
Laragh JH. Assessment of left ventricular function by the midwall fractional 
shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 
1994;23:1444-1451. 
De Simone G, Deveroux RB, Mureddu GF, Roman MJ, Ganau A, Alderman MH, Contaldo F, 
Laragh JH. Influence of obesity on left ventricular midwall mechanics in arterial 
hypertension. Hypertension 1996;28:276-283. 
Deuchar GA, Opie LH, Lecour S. TNFα is required to confer protection in an in vivo model of 
classical ischaemic preconditioning. Life Sci 2007;80:1686-1691. 
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. 
Echocardiograph assessment of left ventricular hypertrophy: comparison to necropsy 
findings. Am J Cardiol 1986;57:450-458. 
91 
 
de Devitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac 
function. Circulation 1981;64:477-482. 
Dong F, Zhang X, Yang X, Esberg LB, Yang H, Zhang Z, Culver B, Ren J. Impaired cardiac 
contractile function in ventricular myocytes from leptin deficient ob/ob obese mice. J 
Endocrinol 2006;188:25-36. 
Dutta J, Fan Y, Gupta N, Fan G, Gėlinas C. Current insights into the regulation of programmed 
cell death by NF-κβ. Oncogene 2006;25:6800-6816. 
du Toit EF, Smith W, Muller C, Strijdom H, Stouthammer B, Woodiwiss AJ, Norton GR, Lochner 
A. Myocardial susceptibility to ischemic-reperfusion injury in a pre-diabetic model of 
dietary-induced obesity. Am J Physiol Heart Circ Physiol 2008;294:H2336-H2343. 
Doyama K, Fujiwara H, Fukimoto M, Tanaka M, Fujiwara Y, Oda T, Inada T, Ohtani S, 
Hasegawa K, Fujiwara T, Sasayama S. Tumour necrosis factor is expressed in the 
cardiac tissue of patients with heart failure. Int J Cardiol 1996;31:391-398. 
Engel D, Peshock R, Armstrong RC, Sivasubramanian N, Mann DL. Cardiac myocyte apoptosis 
provokes adverse cardiac remodeling in transgenic mice with targeted TNF 
overexpression. Am J Physiol Heart Circ Physiol 2004;287:H1303-H1311. 
Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, Doring A, Broeckel 
U, Riegger G, Schunkert H. Prevalence of left ventricular diastolic dysfunction in the 
community: Results from a Doppler echocardiographic-based survey of a population 
sample. Eur Heart J 2003;24:320-328. 
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US 
adults, 1999-2000. JAMA 2002;288:1723-1727. 
Frankel DS, Vasan RS, D’Agostino RB, Benjamin EJ, Levy D, Wang TJ, Meigs JB. Resistin, 
adiponectin and risk of heart failure. J Am Coll Cardiol 2009;53:754-762. 
92 
 
Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) 
expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 
1999;104:271-280. 
Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rosetti L, Barzilai N. 
Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an 
adipokine-mediated process? Diabetes 2002;51:2951-2958. 
Ganau A, Devereux RB, Roman MJ, deSimone G, Pickering TG, Saba PS, Vargiu P, Simongini 
I, Laragh JH. Patterns of left ventricular remodeling in essential hypertension. J Am Coll 
Cardiol 1992;19:1550-1558. 
Geerdts SO, Nys M, De MP, Charpentier J, Albert A, Legrand V, Rompen EH. Systemic release 
of endotoxins induced by gentle mastication: association with periodontitis severity. J 
Periodontol 2002;73:73-78. 
Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR, Wensel R, Coats AJ, Anker SD. 
Pathophysiologic quantities of endotoxin-induced tumour necrosis factor-alpha release in 
whole blood from patients with chronic heart failure. Am J Cardiol 2002;90:1226-1230. 
Giugliano G, Nicoletti G, Grella E, Giugliano F,Esposito K,Scuderi N, D'Andrea F. Effect of 
liposuction on insulin resistance and vascular inflammatory markers in obese women. Br 
J Plast Surg 2004;57:190-194. 
Givalois L, Dornand J, Mekaouche M, Solier MD, Bristow AF, Ixart G, Siaud P, Assenmacher I, 
Barbanel G. Temporal cascade of plasma level surges in ACTH, corticosterone, and 
cytokines in endotoxin-challenged rats. Am J Physiol 1994;267:R164-R170. 
Harden LM, du Plessis I, Poole S, Laburn HP. Interleukin-6 and leptin mediate 
lipopolysaccharide-induced fever and sickness behaviour. Physiol Behav 2006;89:146-
155. 
93 
 
Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, Dorn GW 2nd, Armstrong RC, Kitsis 
RN. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes 
mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 
2003;108:3036-3041. 
He J, Ogden LG, Bazzano LA, Vuppturi S, Loria C, Whelton PK. Risk factors for congestive 
heart failure in US men and women:NHANES I epidemiologic follow-up study. Arch 
Intern Med 2001;161:996-1002. 
Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets 
reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb 
Vasc Biol ;2001:21:968-970. 
Hershberger RE. Familial dilated cardiomyopathy. Prog Ped Cardiol 2005;20:161-168. 
Hobbs RE. Guidelines for the diagnosis and management of heart failure. Am J Ther 
2004;11:467-472. 
Hunga J, Lew WY. Cellular mechanisms of endotoxin-induced myocardial depression in rabbits. 
Circ Res 1993;73:125-34. 
Hungb J, Lew WY. Temporal sequence of endotoxin-induced systolic and diastolic myocardial 
depression in rabbits. Am J Physiol 1993;265:H810-819. 
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, 
Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, 
Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, 
Russell RO, Smith SC, Jr. ACC/AHA guidelines for the evaluation and management of 
chronic heart failure in the adult: Executive summary, a report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines 
(Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart 
Failure):  Developed in Collaboration with the International Society for Heart and Lung 
94 
 
Transplantations;  endorsed by the Heart Failure Society of America. Circulation 
2001;104:2996-3007. 
Iacobellis G, Ribaudo MC, Leto G, Zappaterreno A, Vecci E, DiMario U, Leonetti F. Influence of 
excess fat on cardiac morphology and function. Study in uncomplicated obesity. Obes 
Res 2002;10:767-773. 
Ingelssona E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of 
congestive heart failure. JAMA 2005;294:334-341. 
Ingelssonb E, Arnlov J, Sundstrom J, Lind L. Inflammation, as measured by the erythrocyte 
sedimentation rate, is an independent predictor for the development of heart failure. J 
Am Coll Cardiol 2005;45:1802-1806. 
Ingelsson E, Riserus U, Berne C, Frystyk J, Flyvbjerg A, Axelsson T, Lundmark P, Zethelius B. 
Adiponectin and risk of congestive heart failure JAMA 2006;295:1772-1774. 
Jafri SM, Levine S, Field BE, Bahorozian MT, Carlson RW. Left ventricular diastolic function in 
sepsis. Crit Care Med 1990;18:709-714. 
Johansson S, Wallander MA, Ruigomez A, Garcia Rodriguez LA. Incidence of newly diagnosed 
heart failure in UK general practice. Eur J Heart Fail 2001;3:225-231.  
Kalra D, Svasubramnian N, Mann D. Angiotensin II induces tumour necrosis factor alpha 
biosynthesis in the adult mammalian heart through protein kinase-C dependent pathway. 
Circulation 2002;105:2198-2205.  
Karason K, Wallentin I, Larsson B, Sjostrom L. Effects of obesity and weight loss on cardiac 
function and valvular performance. Obes Res 1998;6:422-429. 
Kelly R, Smith T. Cytokines and cardiac contractile function. Circulation 1997;95:778-781. 
Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson SD, Kannel WB, Vasan 
RS. Obesity and the risk of heart failure. New Engl J Med 2002;347:305-313. 
95 
 
Kenchaiah S, Sesso HD, Gaziano MJ. Body mass index and vigorous physical activity and the 
risk of heart failure among men. Circulation 2009;119:44-52.   
Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, De Lemos JA. Sex differences 
in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab  
2009;94:3251-3258. 
Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH. American 
Heart Association Council on Nutrition, Physical Activity, and Metabolism and American 
College of Cardiology Foundation, Clinical implications of obesity with specific focus on 
cardiovascular disease: a statement for professionals from the American Heart 
Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the 
American College of Cardiology Foundation. Circulation 2004;110:2952–2967. 
Kluger MJ, O'Reilly B, Shope TR, Vander AJ. Further evidence that stress hyperthermia is a 
fever. Physiol Behav 1987;39:763-766. 
Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards 
NM, Itescu S. Neovascularization of ischemic myocardium by human bone-
marrow−derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and 
improves cardiac function. Nat Med 2001;7:430-436. 
Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. 
Impact of weight loss on inflammatory proteins and their association with the insulin 
resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 
2003;23:1042-1047. 
Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with 
sepsis. Curr Opin Crit Care 2002;8:376-388. 
Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, 
Entman ML, Mann DL. Endogenous tumor necrosis factor protects the adult cardiac 
96 
 
myocyte against ischemic-induced apoptosis in a murine model of acute myocardial 
infarction. Proc Natl Acad Sci USA 2000;97:5456-5461. 
Lang A, Froelicher ES. Management of overweight and obesity in adults: behavioral intervention 
for long-term weight loss and maintenance. Eur J Cardiovasc Nurs 2006;5:102-114.  
Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role 
for Sphingolipid signaling in TNFα and ischemic preconditioning mediated 
cardioprotection.J Mol Cell Cardiol 2002;34:509-518. 
Lemieux I, Pascot A, Prud’homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP. 
Elevated C-reactive protein: another component of the atherothrombotic profile of 
abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-967. 
Lenfant C. Report of the task force on research in heart failure. Circulation 1994;90:1118-11123. 
Levine B, Kalman J, Mayer L, Fiuit HM, Packer M. Elevated circulating levels of tumour necrosis 
factor alpha in severe chronic heart failure. N Engl J Med 1990;323:236-241. 
Lew WY, Yasuda S, Yuan T, Hammond HK. Endotoxin-induced cardiac depression is 
associated with decreased cardiac dihydropyridine receptors in rabbits. J Mol Cell 
Cardiol 1996;28:1367-1371. 
Lewa WY, Lee M, Yasuda S, Bayna E. Depyrogenation of digestive enzymes reduces 
lipopolysaccharide tolerance in isolated cardiac myocytes. J Mol Cell Cardiol 
1997;29:1985-1990. 
Lewb WY, Ryan J, Yasuda S. Lipopolysaccharide induces cell shrinkage in rabbit ventricular 
cardiac myocytes. Am J Physiol 1997;272:H2989-H2993. 
Li HL, Suzuki J, Bayna E, Zhang FM, Dalle Molle E, Clark A, Engler RL, Lew WY. 
Lipopolysaccharide induces apoptosis in adult rat ventricular myocytes via cardiac AT1 
receptors. Am J Physiol 2002;283:H461-H467. 
97 
 
Li L, Shigematsu Y, Hamada M, Hiwada K. Relative wall thickness is an independent predictor 
of left ventricular systolic and diastolic dysfunctions in essential hypertension. Hypertens 
Res 2001;24:493-499. 
Libhaber CD, Norton GR, Majane OHI, Libhaber E, Essop, MR, Brooksbank R, Maseko M, 
Woodiwiss AJ. Contribution of central and general adiposity to an abnormal left 
ventricular diastolic function in a community sample with a high prevalence of obesity. 
Am J Cardiol 2009;104:1527-1533. 
Liu CJ, Cheng YC, Lee KW, Hsu HH, Chu CH, Tsai FJ, Tsai CH, Chu CY, Liu JY, Kuo WW, 
Huang CY. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 
signaling pathway in H9c2 myocardiac cells. Mol Cell Biochem 2008;313:167-178. 
Liu PP, Mason JW. Advances in understanding of myocarditis. Circulation 2001;104:1076-1082. 
Luppi P, Rudert WA, Zanone MM, Stassi G, Trucco G, Finegold D, Boyle GJ, Del Nido P, 
McGowan FX Jr, Trucco M. Idiopathic dilated cardiomyopathy: A superantigen-driven 
autoimmune disease. Circulation 1998;98:777-785. 
Maher D, Smeeth L, Sekajugo J. Health transition in Africa: practical policy proposals for 
primary care. Bull World Health Organ 2010;88:943-948.  
Majane OHI, Norton GR, Maseko MJ, Makaula S, Crowther N, Paiker J, Thijs L, Brooksbank R, 
Sareli P, Staessen JA, Woodiwiss AJ. The association of waist circumference with 
ambulatory blood pressure is independent of alternative adiposity indices. J Hypertens 
2007;25:1798-1806. 
Majane OHI, Woodiwiss AJ, Maseko MJ, Crowther N, Dessein P, Norton GR. Impact of age on 
the independent association of adiposity with pulse wave velocity in a population sample 
of African ancestry. Am J Hypertens 2008;21:936-942. 
Mann DL. Inflammatory mediators and the failing heart: past, present and the foreseeable future 
Circ Res 2002;91:988-998. 
98 
 
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J,Drexler H, 
Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, 
Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine 
therapy in patients with chronic heart failure: results of the Randomized Etanercept 
Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602. 
Martich GD, Parker MM, Cunnion RE, Suffredinin AF. Effects of ibuprofen and pentoxifylline on 
the cardiovascular response of normal humans to endotoxin. J Appl Physiol 
1992;73:925-931. 
Matsumori A, Yamada T, Suzuki H, Matonba Y, Sasayama S. Increased circulating cytokines in 
patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-566. 
Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert, H. Functional 
improvement in heart failure patients treated with beta-blockers is associated with a 
decline of cytokine levels. Int J Cardiol 2010;103:182-186. 
Mayet J, Ariff B, Wasan B, Chapman N, Shahi M, Senior R, Foale RA, Thom SA. Midwall 
myocardial shortening in athletic left ventricular hypertrophy. Int J Cardiol 2002;86:233-
238. 
McDonald TE, Grinman Mn, Carthy CM, Walley KR. Endotoxin infusion in rats induces apoptotic 
and survival pathways in hearts. Am J Physiol 2000;279:H2053-H2056. 
Merx MW, Weber C. Sepsis and the heart. Circulation 2007;116:793-802. 
Messerli FH, Sundgaard-Riise K, Resein ED, Dreslinski GR, Ventura HO, Oigman W, Frohlich 
ED, Dunn FG. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann 
Intern Med 1983;99:757-761. 
Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The 
prognosis of heart failure in the general population.  The Rotterdam Study. Eur Heart J 
2001;22:1318-1327. 
99 
 
Moutsopoulos NM, Madianos PN. Low-grade inflammation in chronic infectious diseases: 
paradigm of periodontal infections. Ann N Y Acad Sci 2006;1088:251-264. 
Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Corbellini C, Castellano M, Porteri E, Agabiti-
Rosei E. Changes in midwall systolic performance and cardiac hypertrophy reduction in 
hypertensive patients. J Hypertens 2000;18:1651-1656. 
Muller-Werdan U, Schumann H, Loppnow H, Fuchs R, Darmer D, Stadler J, Holtz J, Werdan K. 
Endotoxin and tumour necrosis factor alpha exert a similar proinflammatory effect in 
neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell 
Cardiol 1998;30:1027-1036. 
Munt B, Jue J, Gin K, Fenwick J, Tweeddale M. Diastolic filling in human severe sepsis: an 
echocardiographic study. Crit Care Med 1998;26:1829-1833. 
Mureddu GF, De Simone G, Greco R, Rosato GF, Contaldo F. Left ventricular filling pattern in 
uncomplicated obesity. Am J Cardiol 1996;77:509-514. 
Neviere R, Fauvel H, Chopin C, Formstecher P, Marchetti P. Caspase inhibition prevents 
cardiac dysfunction and heart apoptosis in a rat model of sepsis. Am J Resp Crit Care 
Med 2001;163:218-225. 
Nicklas BJ, Cesari M, Penninx BWJH, Kritchevsky SB, Ding J, Newman A, Kitzman DW, 
Kanaya AM, Pahor M, Harris TB. Abdominal obesity is an independent risk factor for 
chronic heart failure in older people. J AM Geriatr Soc 2006;54:413-420. 
Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, 
Coats AJ, Anker SD. Endotoxin and immune activation in chronic heart failure: a 
prospective cohort study. Lancet 1999;353:1838-1842. 
Niu J, Azfer A, Kolattukudy PE. Protection against Lipopolysaccharide-induced myocardial 
dysfunction in mice by cardiac-specific expression of soluble Fas. J Mol Cell Cardiol 
2008;44:160-169. 
100 
 
Nishikawa Y, Lew WY. Endotoxin-induced left ventricular depression is blocked by nitrogen 
mustard or dimethylthiourea in rabbits. Am J Physiol 1995;269:H1098-H1105. 
Nishikawa K, Mathison J, Lew WY. Serum tumour necrosis factor-α does not mediate 
endotoxin-induced myocardial depression in rabbits. Am J Physiol 1996;39:H485-H491. 
Norton GR, Woodiwiss AJ, Gaasch WH, Mela T, Chung ES, Aurigemma GP, Meyer TE. Heart 
failure in pressure overload hypertrophy: The relative roles of ventricular remodeling and 
myocardial dysfunction. J Am Coll Cardiol 2002;39:664-671. 
Norton GR, Majane OHI, Libhaber E, Libhaber C, Maseko MJ, Makaula S, Libhaber C, 
Woodiwiss AJ. The relationship between blood pressure and left ventricular mass index 
is dependent on an excess adiposity. J Hypertens 2009;27:1873-1883. 
Norton GR, Maseko M, Libhaber E, Libhaber CD, Majane OHI, Dessein P, Sareli P, Woodiwiss 
AJ. Is pre-hypertension an independent predictor of target organ changes in young-to-
middle aged persons of African descent? J Hypertens 2008;26:2279-2287. 
Nsubuga P, Nwanyanwu O, Nkengasong JN, Mukanga D, Trostle M. Strengthening public 
health surveillance and response using the health systems strengthening agenda in 
developing countries. BMC Public Health 2010;10:S5. 
Nunez E, Arnett DK, Benjamin EJ, Liebson PR, Skelton TN, Taylor H, Andrew MS. Optimal 
threshold value for left ventricular hypertrophy in blacks from the Atherosclerosis Risk in 
Communities study. Hypertension 2005;45:58-63. 
O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, 
Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P.  
European Society of Hypertension Working Group on Blood Pressure Monitoring. 
European Society of Hypertension recommendations for conventional, ambulatory and 
home blood pressure measurement. J Hypertens 2003;21:821-848. 
101 
 
Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 
2007;132:2087-2102. 
Olubodun JO Lawal SO. Alcohol consumption and heart failure in hypertensives. Int J Cardiol 
1996;53:81-85. 
Osadchii O, Norton G, Woodiwiss A. Inotropic responses to phosphodiesterase inhibitors in 
cardiac hypertrophy in rats. Eur J Pharmacol 2005;514:201-208. 
Osadchii OE, Norton GR, McKechnie R, Defterios D, Woodiwiss AJ. Cardiac dilatation and 
pump dysfunction without intrinsic myocardial systolic failure following chronic β-
adrenoreceptor activation. Am J Physiol 2007;292:246-253. 
Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, 
Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. 
Ann Intern Med 1984;100:483-490. 
Pascual M, Pascual DA, Soria F, Vicente T, Hernandez AM, Tebar FJ, Valdes M. Effects of 
isolated obesity on systolic and diastolic left ventricular function. Heart 2003;89:1152-
1156. 
Peng T, Lu X, Feng Q. NADH oxidase signalling induces cyclooxygenase-2 expression during 
lipopolysacchardie stimulation in cardiomyocytes. FASEB J 2005; 19:293-295.  
Peterson LR, Waggoner AD, Schechtmann KB, Meyer T, Gropler RJ, Barzilia B, Davila-Romain 
VG. Alterations in left ventricular structure and function in young healthy obese women. 
J Am Coll Cardiol 2004;43:1399-1404. 
Piche ME, Lemieux S, Weisnagel SJ, Corneua L, Nadeau A, Bergeron J. Relation of high-
sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to 
abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in 
healthy postmenopausal women. Am J Cardiol 2005;96:92-97. 
102 
 
Poelaert J, Declerek C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and 
diastolic function in septic shock. Intensive care Med 1997;23:553-560. 
Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004;95:1140-1153. 
Puoane T, Steyn K, Bradshaw D, Laubscher R, Fourie J, Lambert V, Mbananga N.  Obesity in 
South Africa: the South African demographic and health survey. Obes Res 
2002;10:1038-1048. 
Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of 
systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of 
the heart failure epidemic. JAMA 2003;289:194-202. 
Reilly JM, Cunnion RE, Burch-Whitman C, Parker MM, Shelhamer JH, Parrillo JE. A circulating 
myocardial depressant substance is associated with cardiac dysfunction and peripheral 
hypoperfusion (lactic acidemia) in patients with septic shock. Chest 1989;95:1072-1080. 
Relling DP, Esberg LB, Fang CX, Johnson WT, Murphy EJ, Carlson EC, Saari JT and Ren J. 
High-fat diet induced juvenile obesity leads to cardiomyocyte dysfunction and 
upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J 
Hypertens 2006;24:549-561. 
Ren J, Sowers JR, Walsh MF, Brown RA. Reduced contractile response to insulin and IGF-I in 
ventricular myocytes from genetically obese Zucker rats. Am J Physiol  
2000;279:H1708-H1714. 
Rider OJ, Francis JM, Ali MK, Peterson SE, Robinson M, Robson MD, Byrne JP, Clarke K, 
Neubauer S. Beneficial cardiovascular effects of bariatric surgical and dietary weight 
loss in obesity. J Am Coll Cardiol 2009;54:718-726. 
Ridker PM, Buring JE. C-Reactive Protein, the metabolic syndrome and risk of cardiovascular 
events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 
2003;107:391-397. 
103 
 
Rosengarten B, Hecht M, Wolff S, Kaps M. Autoregulative function in the brain in an endotoxic 
rat shock model. Inflamm Res 2008;57:542-546. 
Roth J, Conn C, Kluger MJ, Zeisberger E. Release of interleukin-6 and tumor necrosis factor 
during lipopolysaccharide induced fever in guinea pigs. 8th International Symposium 
Pharmacology of Thermoregulation, Kananaskis, Alberta, Canada. 1991. 
Roth J, Hubschle T, Pehl U, Ross G, Gerstberger R. Influence of systemic treatment with 
cyclooxygenase inhibitors on lipopolysaccharide-induced fever and circulating levels of 
cytokines and cortisol in guinea pigs. Pflugers Arch 2002;443:411-417. 
Roth J, McClellan JL, McClellan JL, Kluger MJ, Zeisberger E. Attenuation of fever and release 
of cytokines after repeated injections of lipopolysaccharide in guinea-pigs. J Physiol 
1994;477:177-185. 
Sahn DJ, de Maria A, Kisslo J, Weyman A. The committee on M-mode standardization of the 
American Society of Echocardiography: Recommendations regarding quantitation in M-
mode echocardiography: results of a survey of echocardiographic measurements. 
Circulation 1978;58:1072-1083. 
Sam F, Duhaney TA, Sato K, Wilson RM, Ohashi K, Sono-Romanelli S, Higuchi A, De Silva DS, 
Walsh K, Ouchi N. Adiponectin defeiciency, diastolic dysfunction, and diastolic heart 
failure. Endocrinology 2010;151:322-331. 
Sarkar S, Chawla-Sarkar M, Young D, Nishiyama K, Rayborn ME, Hollyfield JG, Sen S. 
Myocardial cell death and regeneration during progression of cardiac hypertrophy to 
heart failure. J Biol Chem 2004;279:52630-52642. 
Seftel HC. Cardiomyopathies in Johannesburg Bantu. Part I: Aetiology and characteristics of 
Beriberi heart disease. S Afr Med J 1972;46:1707-1713. 
104 
 
Scaglione R, Dichiara MA, Indovina A, Lipari R, Ganguzza A, Parrinello G, Capuana G, Merlino 
G, Licata G. Left ventricular diastolic and systolic function in normotensive obese 
subjects: influence of degree and duration of obesity. Eur Heart J 1992;13:738-742. 
Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, 
Ohashi K, Funahashi T, Colucci WS, Walsh K.. Adiponectin-mediated modulation of 
hypertrophic signals in the heart. Nat Med 2004;10:1384-1389. 
Skilton MR, Sieveking DP, Harmer JA, Franklin J, Loughnan G, Nakhla S, Sullivan DR, 
Caterson JD, Celermajer DS. The effects of obesity and non-pharmacological weight 
loss on vascular and ventricular function and structure. Diabet Obes Metab 2007;10:874-
884. 
Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of 
pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy. Lancet 
1998;351:1091-1093. 
Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S. Spectrum of 
heart disease and risk factors in a black urban population in South Africa (the Heart of 
Soweto Study): a cohort study. Lancet 2008;371:915-922. 
Spies C, Farzaneh-Far R, Na B, Kanaya A, Schiller N, Whooley MA. Relations of obesity to 
heart failure hospitalization and cardiovascular events in persons with stable coronary 
heart disease (from the Heart and Soul Study). Am J Cardiol 2009;104:883-889. 
Stein B, Frank P, Schmitz W, Scholz H, Thoenes M. Endotoxin and cytokines induce direct 
cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide 
synthase. J Cell Mol Cardiol 1996;28:1631-1639. 
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer?  
Five-year survival following a first admission for heart failure. Eur J Heart Fail 
2001;3:315-322. 
105 
 
Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, Sliwa K.  Predominance 
of heart failure in the heart of Soweto study cohort: Emerging challenges for urban 
African communities. Circulation 2008;118:2360-2367. 
Stoddard MF, Tseuda K, Thomas M, Dillon S, Kupersmith J. The influence of obesity on left 
ventricular filling and systolic function. Am Heart J 1992;124:694-699. 
Suffredini, AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The 
cardiovascular response of normal humans to the administration of endotoxin. N Engl J 
Med 1989;321:280-287. 
Sutton-Tyrrell K, Newman A, Simonsick EM, Havlik R, Pathor M, Lakatta E, Spurgeon H, 
Vaitkevicius P. Aortic stiffness is associated with visceral adiposity in older adults 
enrolled in the study of health, aging, and body composition. Hypertension 2001:38:429-
433. 
Suzuki J, Bayna E, Molle ED, Lew WY. Nicotine inhibits cardiac apoptosis induced by 
lipopolysaccharide in rats. J Am Coll Cardiol 2003;41:482-488. 
Suzuki J, Bayna E, Li HL, Molle ED, Lew WY. Lipopolysaccharide activates calcineurin in 
ventricular myocytes. J Am Coll Cardiol 2007;49:491-499. 
Tanno M, Gorog DA, Bellahcene M, Cao X, Quinlan RA, Marber MS. Tumor necrosis factor-
induced protection of the murine heart is independent of p38-MAPK activation. J Mol 
Cell Cardiol 2003;35:1523-1527. 
Tao S, McKenna TM. In vitro endotoxin exposure induces contractile dysfunction in adult rat 
cardiac myocytes. Am J Physiol 1994;267:H1745-H1752. 
Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen HV, Kubes P. Immune cell Toll-
Like Receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ 
Res 2004;95:700-707. 
106 
 
Teichholz LE, Krelen T, Herman MV, Gorlin R. Problems in echocardiographic volume 
determinations: echocardiographic-angiographic correlations in the presence of absence 
of synergy. Am J Cardiol 1976;37:7-11. 
Torre-Amionea G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumour 
necrosis factor and tumour necrosis factor receptors in the failing human heart. 
Circulation 1996;93:704-711. 
Torre-Amioneb G, Capaslera S, Benedict C, Oral Y, Young JB, Mann DL. Pro-inflammatory 
cytokine levels in patients with depressed left ventricular ejection fraction: a report from 
the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-
1206. 
Torre-Amione G, Stetson SJ, Youker KA, Durand JB, Radovancevic B, Delgado RM, Frazier 
OH, Entman ML, Noon GP. Decreased expression of TNFα in failing human myocardium 
after mechanical circulatory support: A potential mechanism of cardiac recovery. 
Circulation 1999;100:1189-1193. 
Tsioufis CP, Tsiachris DL, Selima MN, Diminitriadis KS, Thomopoulos CG, Tsiliggiris DC, 
Gennadi AS, Syrseloudis DC, Stefanadi ES, Toutouzas KP, Kallikazaros IE, Stefanadis 
CI. Impact of waist circumference on cardiac phenotypes in hypertensives according to 
gender. Obesity 2009;17:177-182. 
Vasan R, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, 
Wilson PWF, D’Agostino RB. Imflammatory markers and risk of heart failure in elderly 
subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 
2003;107:1486-1491. 
Veliotes DGA, Woodiwiss AJ, Deftereos D, Gray D, Osadchii O, Norton GR. Aldosterone 
receptor blockade prevents the transition to cardiac pump dysfunction induced by β-
adrenoreceptor activation. Hypertension 2005;45:914-920. 
107 
 
Wiggers CJ. Myocardial depression in shock: a survey of cardiodynamic studies. Am Heart J 
1947;33:633-650. 
Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of 
men: morbidity, risk factors and prognosis. J Intern Med 2001;249:253-261. 
Willens HJ, Chakko SC, Byers P, Chirinos JA, Labrador E, Castrillon JC, Lowery MH. Effects of 
weight loss after gastric bypass on right and left ventricular function assessed by tissue 
Doppler imaging. Am J Cardiol 2005;95:1521-1524. 
Wong CY, O’Moore-Sullivan T, Leano r, Byrne N, Beller E, Marwick TH. Alterations of left 
ventricular myocardial characteristics associated with obesity. Circulation 
2004;110:3081-3087. 
Wong CY, Byrne NM, O’Moore-Sullivan T, Hills AP, Prins JB, Marwick TH. Effect of weight loss 
due to lifestyle intervention on subclinical cardiovascular dysfunction in obesity (body 
mass index >30 kg/m2). Am J Cardiol 2006;98:1593-1598. 
Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. 
A reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat 
models of systolic chamber dysfunction. Circulation 2001;103:155-160. 
Woodiwiss AJ, Libhaber CD, Majane OHI, Libhaber E, Maseko M, Norton GR. Obesity 
promotes left ventricular concentric rather than eccentric geometric remodeling and 
hypertrophy independent of blood pressure. Am J Hypertens 2008;21:1144-1151. 
Woodiwiss AJ, Molebatsi N, Maseko MJ, Libhaber E, Libhaber C, Majane OHI, Paicker J, 
Dessein P, Brooksbank R, Sareli P, Norton GR. Nurse-recorded auscultatory blood 
pressure at a single visit predicts target organ changes as well as ambulatory blood 
pressure. J Hypertens 2009;27:287-297. 
108 
 
Yasudaa S, Lew WY. Lipopolysaccharide depresses cardiac contractility and β-adrenergic 
contractile response by decreasing myofilament response to Ca2+ in cardiac myocytes. 
Circ Res 1997;81:1011-1020.  
Yasudab S, Lew WY. Endothelin-1 ameliorates contractile depression by lipopolysaccharide in 
cardiac myocytes. Am J Physiol 1997;273:H1403-H1407. 
Yasuda S, Lew WY. Angiotensin II exacerbates lipopolysaccharide-induced contractile 
depression in rabbit cardiac myocytes. Am J Physiol 1999;276:H1442-H1449. 
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: 
associations with obesity, insulin resistance, and endothelial dysfunction: a potential role 
for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 
1999;19:972-978. 
Zarich SW, Kowalchuk GJ, McGuire MP, Benotti PN, Mascioli EA, Nesto RW. Left ventricular 
filling abnormalities in asymptomatic morbid obesity. Am J Cardiol 1991;68:377-381. 
Zhou Y-T, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. 
Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Nat Acad Sci 
2000;97:1784-1789. 
109 
 
 
110 
 
 
111 
 
 
